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Delta like ligand 4 is a critical regulator of bone marrow cell differentiation into
pericytes/vascular smooth muscle cells and is essential for the vasculogenesis that
supports the growth of Ewing’s sarcoma

Publication No. ______
Keri Schadler Stewart, B.S.
Supervisory Professor: Eugenie S. Kleinerman, M.D.

We have previously shown that vasculogenesis, the process by which bone marrowderived cells are recruited to the tumor and organized to form a blood vessel network de
novo, is essential for the growth of Ewing’s sarcoma. We further demonstrated that these
bone marrow cells differentiate into pericytes/vascular smooth muscle cells(vSMC) and
contribute to the formation of the functional vascular network. The molecular
mechanisms that control bone marrow cell differentiation into pericytes/vSMC in
Ewing’s sarcoma are poorly understood. Here, we demonstrate that the Notch ligand
Delta like ligand 4 (DLL4) plays a critical role in this process. DLL4 is essential for the
formation of mature blood vessels during development and in several tumor models.
Inhibition of DLL4 causes increased vascular sprouting, decreased pericyte coverage, and
decreased vessel functionality. We demonstrate for the first time that DLL4 is expressed
by bone marrow-derived pericytes/vascular smooth muscle cells in two Ewing’s sarcoma
xenograft models and by perivascular cells in 12 out of 14 patient samples. Using
dominant negative mastermind to inhibit Notch, we demonstrate that Notch signaling is
essential for bone marrow cell participation in vasculogenesis. Further, inhibition of
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DLL4 using either shRNA or the monoclonal DLL4 neutralizing antibody YW152F led
to dramatic changes in blood vessel morphology and function. Vessels in tumors where
DLL4 was inhibited were smaller, lacked lumens, had significantly reduced numbers of
bone marrow-derived pericyte/vascular smooth muscle cells, and were less functional.
Importantly, growth of TC71 and A4573 tumors was significantly inhibited by treatment
with YW152F. Additionally, we provide in vitro evidence that DLL4-Notch signaling is
involved in bone marrow-derived pericyte/vascular smooth muscle cell formation outside
of the Ewing’s sarcoma environment. Pericyte/vascular smooth muscle cell marker
expression by whole bone marrow cells cultured with mouse embryonic stromal cells was
reduced when DLL4 was inhibited by YW152F. For the first time, our findings
demonstrate a role for DLL4 in bone marrow-derived pericyte/vascular smooth muscle
differentiation as well as a critical role for DLL4 in Ewing’s sarcoma tumor growth.
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Chapter 1.
Introduction
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Ewing’s Sarcoma
Ewing’s sarcoma is the second most common pediatric bone cancer, and it
accounts for about 2% of all pediatric malignancies 1. The peak incidence is at age 15,
and it is slightly more prevalent in males than females 2. Although the most common sites
of occurrence are the pelvic bone, the femur, and the ribs, Ewing’s sarcoma can occur in
any bone or soft tissue. The lungs, for example, are a common site for metastatic lesions.
The site of the primary tumor weakly correlates with patient survival; patients with
axially located tumors have a slightly worse prognosis than those with tumors in the
appendicular skeleton 3.
Patients with Ewing’s sarcoma often present initially with pain at the site of the
tumor, or less frequently with swelling or a palpable mass. Although MRI, CT, and PET
scans are used to determine the number and location of tumors present, these are not
diagnostic. A biopsy is needed to diagnose Ewing’s sarcoma by examination of the DNA.
The molecular hallmark of Ewing’s sarcoma is the t(11;22)(q24;q12) translocation,
which creates an EWS-Fli1 fusion protein. This EWS-Fli1 fusion protein is present in
85% of Ewing’s sarcomas, and the remaining 15% harbor a translocation that fuses the
EWS gene to another member of the ETS family 2,3. The presence of an EWS-ETS family
fusion is a definitive indicator of Ewing’s sarcoma.
The current standard of care for Ewing’s sarcoma includes a combination of
preoperative and adjuvant chemotherapy along with local control. Surgery is the
preferred method of local control, but in cases where surgical resection is not possible,
radiation therapy is used 1. First line chemotherapy includes a combination of five drugs:
vincristine, cyclophosphamide, doxorubicin, ifosfamide, and etoposide 4. This
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combination therapy achieves a nearly 70% survival rate for patients with non-metastatic
disease 4. However, the vast majority of patients with Ewing’s sarcoma have metastatic
disease at the time of diagnosis or develop metastases after the first round of therapy.
Unfortunately, for these patients, 5 year survival remains around 25%, even with current
combination therapies 1,4.
The need for new therapeutic options for patients with Ewing’s sarcoma is clear.
One possible way to inhibit tumor growth is by preventing the tumor from developing a
vascular supply, essentially starving the tumor of nutrients and oxygen. Understanding
the molecular mechanisms that direct blood vessel formation in Ewing’s sarcoma is key
to identifying therapeutic targets that might prevent vascular development. The research
presented in this dissertation is intended to contribute to the understanding of the process
of vascular development in Ewing’s sarcoma in order to identify new molecular targets
for inhibiting this process.
Blood Vessel Structure
Our goal is to understand the mechanisms by which tumors form blood vessels in
order to target this process. Therefore, we must first have a basic understanding of the
cellular organization of a blood vessel. In most blood vessels, the lumen, or inner tube
through which blood flows, is surrounded by a single layer of endothelial cells. In arteries
and veins, these endothelial cells are surrounded by one or several layers of mural cells.
Mural cells include pericytes and vascular smooth muscle cells. Varying amounts of
connective tissue, including collagen, elastic fibers, and other proteins and
polysaccharides, are interspersed between and surround the cells of blood vessels.
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Defining pericytes and vascular smooth muscle cells
Defining a pericyte separately from a vascular smooth muscle cell (vSMC) cell is
challenging due to the continuum of phenotypes between the two cell types 5. Generally,
a pericyte is defined as a periendothelial cell within the basement membrane of a blood
vessel which physically contacts endothelial cells, while a vSMC is outside of the
basement membrane and does not directly contact endothelial cells 6. The two cell types
are sometimes differentiated on the basis of the type of vessel that they are a part of;
pericytes typically surround capillaries and microvessels while vSMC surround larger
vessels and arteries 5,6.
Although these definitions can be helpful, they are not finite and are not without
controversy. Evidence for both mesodermal and neuroectodermal origin of both pericytes
and vSMC supports the possibility that pericytes and vSMC may be phenotypic
variations of the same cell type5,7. The identification of a pericyte versus a vSMC is
further complicated by the fact that both can express several of the same proteins in vitro
and in vivo. These markers include alpha-smooth muscle actin (α-SMA), desmin,
regulator of g-protein signaling 5 (RGS5), neuron-glial 2 (NG2) and platelet-derived
growth factor receptor-beta (PDGFR-β). No single marker is expressed by all pericytes
or vSMC and no single marker is expressed only by pericytes or vSMC 6,8,9. For the
purpose of this thesis, the term ‘pericyte/vSMC’ will be used to refer to mural cells
surrounding CD31+ endothelial cells and expressing at least one of the following: αSMA, desmin, RGS5, NG2, PDGFR-β.
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Pericyte Morphology and Function
For an extensive review of historical and current knowledge about pericyte
function, morphology, development, and relationship to endothelial cells, please see
Diaz-Flores et al, 2009 5.
Pericyte morphology can vary based on the tissue location and type of vessel that
it is associated with 8. Most often, the pericyte cell body (nuclear body) is small and oval
(though it can be elongated) with several highly branched processes protruding outward.
Primary processes are often oriented parallel to the vascular axis, with secondary
protrusions wrapping around the endothelial tube. Partial overlap of processes from two
or more pericytes is seen in some vessels, forming multiple layers of pericyte coverage 5.
Pericyte processes connect to multiple endothelial cells, often forming “umbrellalike structures that cover gaps between endothelial cells” 5. The number of pericytes
covering each vessel differs based on species, tissue, type and maturation stage of the
vessel. Some vessels have few or no pericytes, while others, such as those found in the
human retina, have a high pericyte density and a 1:1 pericyte to endothelial cell ratio 5.
Pericytes have several functions relating to vessel structural stability, regulation
of blood flow, and vessel maturation 5,8,10. Pericytes contribute to vessel structural
stability both by secreting matrix proteins, which fortify the basement membrane, and by
directly surrounding endothelial cells to form an outer cell layer 5. During angiogenic
growth, pericytes become activated and enter a period of rapid proliferation, dissociate
from endothelial cells, and secrete basement membrane degrading proteins such as MMP2 5. Additionally, pericytes function to protect vessels from regression 11. During
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retinopathy of prematurity, for example, the degree of vessel coverage with desmin+
pericytes/vSMC correlates with vessel protection12.
Pericyte regulation of blood flow and perfusion is partially mediated by the
adherens junctions formed between pericytes and endothelial cells. These adherens
junctions allow mechanical contractile force to be transmitted from pericytes, which are
contractile cells, to endothelial cells 13 .
In addition to adherens junctions, gap junctions between pericytes and endothelial
cells foster cell-cell communication. Gap junctions allow direct sharing of cytoplasmic
contents such as ions and small molecules to mediate endothelial cell quiescence or
proliferation. Pericytes also communicate with endothelial cells by secreting factors
including vascular endothelial growth factor (VEGF), and angiopoietin-1 (Ang1), which
promote endothelial cell survival and/or proliferation. It is important to note that
communication between endothelial cells and pericytes is bi-directional, and endothelial
cells also provide pro-survival and maturation signals, such as platelet derived growth
factor BB (PDGF-BB) and transforming growth factor beta (TGF-β), to pericytes 10,14.
vSMC morphology and function
Similar to pericytes, vSMC can display several different phenotypes. These
phenotypes range from the synthetic phenotype, where cells are typically rhomboid
shaped, to the contractile phenotype, where cells are elongated and spindle-shaped 7,8.
The synthetic phenotype is so named because during this stage, vSMC synthesize
proteins and extracellular matrix at high rates. Generally, synthetic vSMC have qualities
necessary during vascular remodeling such as high proliferation rates and migratory
abilities. On the other end of the vSMC spectrum, contractile vSMC are senescent, with
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low metabolic activity. Contractile vSMC are named for their contractile properties,
partially due to the high expression of contractile filament proteins such as α-SMA and
desmin 7.
The phenotypic state of vSMC is influenced by several factors, including shear
stress, vicinity to endothelial cells, and molecular cues from the microenvironment.
PDGF-B, for example, induces differentiation and maturation of mesenchymal precursors
into vSMC, but induces a change from contractile to synthetic phenotype in mature
vSMC 8.
The primary function of vSMC is the regulation of arterial tone and blood flow by
providing contractile forces 15. In addition to this, vSMC (like pericytes) secrete a number
of extracellular matrix proteins including collagen, proteoglycans, and cadherins.
Additionally, similar to pericyte regulation of endothelial cell proliferation and
quiescence, vSMC can also form gap junctions with endothelial cells, allowing for direct
communication between the two cell types 16.
Inhibiting pericyte/vSMC formation inhibits vessel function
In a simplified understanding, pericytes/vSMC can be viewed as the protectors of
vascular integrity. Ultimately, defective pericyte/vSMC coverage induces poorly
organized and leaky vasculature5. Using a model of postnatal retina remodeling,
Benjamin et al. demonstrated that pericyte coverage protects blood vessels from the
regression normally induced by hyperoxia. Further, they showed that disruption of
endothelial-pericyte adhesion by intraocular injection of PDGF-BB resulted in excessive
regression of vascular loops 17. Therefore, inhibiting pericyte/vSMC formation is
expected to make blood vessels more susceptible to death or regression. Considering anti-
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vascular therapy in the tumor biology context, inhibiting pericytes/vSMC may lead to
vessel regression, especially in combination with endothelial cell targeting agents,
essentially starving the tumor of its blood supply.
Vasculogenesis
Angiogenesis versus Vasculogenesis
There are two main processes by which blood vessels are formed; angiogenesis
and vasculogenesis. Angiogenesis is the sprouting of pre-existing vessels to form new
ones. During angiogenesis, endothelial cells and pericytes proliferate and migrate, so that
new blood vessels are formed by a locally derived cell population. Alternatively,
vasculogenesis is the process by which bone marrow (BM)-derived precursor cells are
recruited to sites of developing vasculature and organized to form a vessel network de
novo. Vasculogenesis occurs during embryogenesis, and refers to the initial formation of
the vasculature. Originally, it was believed that postnatal vascular development occurred
only by angiogenesis, but several studies have highlighted the important role of
vasculogenesis in postnatal processes such as the healing of cutaneous wounds, in
response to ischemia, and more recently, in tumor growth. Angiogenesis and
vasculogenesis both contribute to vascular growth in adults, and the level of contribution
of each varies based on the tissue and stimulus18.
Vasculogenesis
A simplified explanation of the series of events that occur during prenatal
vasculogenesis is as follows: Splanchnic mesoderm cells arise from the cells of the lateral
plate mesoderm, and from these, hemangioblasts are formed. Hemangioblasts are the
common progenitor to both endothelial and hematopoietic cells. Hemangioblasts cluster
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to form blood islands, which then form a network of tubules known as the capillary
plexus. After the initial formation of a capillary plexus, pericytes and vSMC are required
for remodeling into a functional circulatory network 19. Recent evidence suggests that the
hemangioblasts in blood islands can be subdivided into two progenitor groups: those that
become either endothelial cells or hematopoietic cells, and those that become
pericytes/vSMC 20. Traditionally, pericyte/vSMC ontogeny is thought to depend on the
location of the blood vessel, but most pericytes/vSMC are believed to be derived from the
mesoderm or neural crest 18,19.
The process of postnatal vasculogenesis is less fully understood. In postnatal
vasculogenesis, the vascular progenitor cells originate from a pool of pluripotent stemlike cells in the BM. The presence of BM-derived endothelial cells and pericytes/vSMC
has been documented in several physiologic and pathologic situations. For example, a
series of BM transplant studies by Asahara et al. provided early evidence for the
incorporation of BM-derived precursors as endothelial cells during vasculogenesis after
ovulation, during wound healing, in response to ischemia, and finally during tumor
growth in mice 21-23. The contribution of BM-derived endothelial precursor cells to
vasculogenesis in several postnatal models, including tumors, has now been extensively
documented 24.
BM-derived pericytes/vSMC have also been shown to participate in postnatal
vasculogenesis. Recently, using a mouse BM transplant model, BM-derived vSMC were
found in the healed femoral artery of a mouse after wire induced injury 25. BM-derived
pericytes/vSMC have also been identified in tumors. Rajantie et al identified NG2+ BMderived perivascular cells in B16 melanomas in mice 26. Additionally, Du et al
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demonstrated that BM-derived cells become desmin+ and α-SMA+ cells and incorporate
into the vasculature of glioblastomas in mice 27.
Vasculogenesis in Ewing’s sarcoma
We have previously shown that bone marrow(BM)-derived cells participate in
vascular formation in Ewing’s sarcoma by differentiating into both endothelial cells and
pericytes 28,29. The contribution of BM cells to the endothelial cell population within the
tumor is relatively small; about 10% of vessels have at least one BM derived endothelial
cell 28. However, a much larger portion of vessels contain BM-derived pericytes/vSMC.
The pericytes/vSMC component of the majority of the blood vessels in Ewing’s
sarcoma is a mosaic of BM-derived and locally derived cells, indicating a combination of
angiogenesis and vasculogenesis 29-31. This was demonstrated using a GFP BM transplant
model. Nude mice recipients were lethally irradiated to eradicate endogenous BM and
then rescued with GFP+ BM from GFP transgenic mice. After engraftment of the GFP+
BM cells, TC71 Ewing’s sarcoma cells were injected subcutaneously and allowed to
form tumors. Tumors were then removed and immunohistochemistry was performed.
Analysis of these tumors revealed thick layers of GFP+ BM-derived cells surrounding
CD31+ endothelial cells. Co-staining for GFP and the pericyte/vSMC markers desmin, αSMA, and PDGFR-β demonstrated that many of the GFP+ BM-derived cells also
expressed pericyte/vSMC markers, indicating that BM cells differentiate into
pericyte/vSMC in Ewing’s sarcoma in vivo 29.
BM cell participation in vasculogenesis is a complex, multi-step process. BM
progenitors must be recruited to the tumor, retained at sites of developing vasculature,
and then differentiate into endothelial cells and pericytes/vSMC. Understanding the
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molecular signals in each step of the vasculogenesis process may lead to the
identification of new targets for the inhibition of vasculogenesis, ultimately identifying
possible therapeutic agents for the treatment of Ewing’s sarcoma.
We have previously demonstrated that VEGF165 is the major chemotactic
stimulant for the recruitment of BM-derived cells to the tumor 32. shRNA was used to
specifically inhibit the expression of VEGF165 by TC71 Ewing’s sarcoma cells, creating
a stable TC/siVEGF165 clone. TC/siVEGF165 cells were injected subcutaneously into
mice and allowed to form tumors. Fluorescently labeled BM cells were then injected
intravenously into tumor bearing mice. TC/siVEGF165 cells formed smaller, slower
growing tumors in vivo than parental TC71 cells or TC/si control. Importantly,
TC/siVEGF165 had decreased microvessel density and reduced numbers of BM-derived
cells. This experiment demonstrates the essential role of VEGF165 in recruiting and
retaining BM-derived cells in the tumor 32.
To further confirm the importance of vasculogenesis in Ewing’s sarcoma growth,
the chemokine stromal cell derived factor-1 alpha (SDF-1α) was used 33. SDF-1α is a
chemoattractant for BM progenitor cells, but has little or no effect on local angiogenesis
and does not stimulate tumor cell proliferation. Bilateral TC/siVEGF165 were implanted
into both flanks of nude mice. Tumors were then treated with intratumor injections of
adenoviral SDF-1α (Ad-SDF-1, right side tumors) or adenoviral control (Ad-control, left
side tumors). Ad-SDF-1α tumors had more infiltrated GFP+ BM-derived cells that
contributed to larger, more organized blood vessels than Ad-control treated tumors.
Importantly, the increased influx of BM cells and subsequent increased vascularity
caused by SDF-1α was able to partially rescue tumor growth even in the absence of
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VEGF165; Ad-SDF1α treated tumors were larger than their Ad-control counterparts. The
increased participation of BM-derived cells in vascular formation in Ad-SDF-1α treated
tumors and the subsequent increase in tumor growth suggests that the formation of BMderived vascular cells is important for Ewing’s sarcoma tumor growth 33.
BM-cell participation in vasculogenesis in Ewing’s sarcoma and the important
contribution of this process to tumor growth is well established 28,29,34. VEGF165 is a key
chemoattractant recruiting BM progenitor cells to Ewing’s sarcoma tumors. Once BM
cells reach the tumor, however, they must adhere to sites of developing vasculature and
differentiate into endothelial cells and/or pericytes/vSMC. The majority of vessels within
Ewing’s sarcoma tumors have perivascular BM-derived cells. Several of the vessels that
have perivascular BM-derived cells are only partially surrounded by these cells, as shown
in figure 1. This phenotype implies that a combination of angiogenesis and
vasculogenesis occurs in Ewing’s sarcoma. It further implies that molecular signals on
some developing vessels direct incoming BM cells to adhere and participate in vascular
formation, while other vessels do not have these signals. The molecular mechanisms that
direct BM progenitor cells to adhere to certain vessels but not others and to differentiate
into pericytes/vSMC are unknown. One family of signaling molecules known to be
important in vascular formation during embryonic development as well as in adult
angiogenesis and vasculogenesis is the Notch family of ligands and receptors. As
explained in the next section, the Notch signaling pathway, in particular the Notch ligand
DLL4, is likely plays to play an important role in directing BM-derived cells to
participate in vasculogenesis in Ewing’s sarcoma by controlling their differentiation into
pericytes/vSMC.
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GFP BM cells / nuclei

A

GFP BM cells / CD31

B

Figure 1. BM-derived cells surround the majority, but not all, blood vessels in
Ewing’s sarcoma. TC71 cells were implanted subcutaneously into nude mice that had
previously received GFP BM transplants and allowed to form tumors. 3 weeks later,
tumors were harvested, frozen and cryosectioned for immunohistochemical evaluation.
A) Immunohistochemistry was performed to identify GFP+ BM-derived cells (green) and
nuclei (blue). B) Immunohistochemistry was performed to identify GFP+ BM-derived
cells (green) and CD31+ endothelial cells (red). White arrows indicate blood vessels that
do not have perivascular BM-derived cells.
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Notch
The Notch family is an evolutionarily conserved group of ligands and receptors
that regulate diverse biologic processes including cell fate assignment, stem cell
maintenance, and boundary formation during development 35. The mammalian Notch
family includes four heterodimeric transmembrane receptors, Notch 1-4, and five
transmembrane ligands, Jagged 1,2 and Delta like ligand 1,3,4 (DLL1-4).
The canonical Notch signaling pathway has been well described. Ligand binding
activates Notch receptors, which induces two cleavage events. The first cleavage,
mediated by an ADAM-type protease, leads to a conformational change in the receptor
that exposes the second cleavage site. The Notch Intracellular Domain (NICD) is released
by a second cleavage, performed by the proteolytic γ-secretase/presenilin complex. After
NICD is cleaved from the transmembrane and extracellular domains, it translocates to the
nucleus, where it complexes first with Recombination Signal Binding Protein 1 for J-κ
(RBP-Jκ, also known as CSL) and then with one of three Mastermind like proteins
(MAML1-3). This RBP-Jk/MAML complex recruits other co-activators, including p300,
and releases co-repressors to induce transcription of downstream Notch effectors. The
Notch effectors are themselves basic Helix-loop-Helix transcription factors, including
Hairy Enhancer of Split (Hes) and Hairy-related (Hey) family members 36,37.
Non-canonical Notch signaling has also been reported, but is beyond the scope of
this thesis 37.
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Figure 2. The Notch Signaling Pathway. A) Structural domains of Notch ligands and
receptors. The five Notch ligands, Delta like ligand 1 (DLL1), DLL3, DLL4, Jagged 1
(Jag1) and Jag2 each have a small intracellular region, a transmembrane region, and an
extracellular portion that can bind to Notch receptors on an adjacent cell. Jag1 and Jag2
contain cysteine-rich domains. All of the ligands contain EGF-like repeats (Jag1 and Jag2
have 18, DLL3 has 6, and DLL1 and DLL4 have 8) and a DSL (delta-serrate-lag)
domain. The Notch receptors are heterodimers. The external subunits contain varying
numbers of EGF-like repeats (Notch1 has 36, Notch4 has 29) and a Lin12 domain. The
subunit containing the intracellular domain (NICD) is a made up of a transmembrane
region (with a γ-secretase cleavage site), an internal RAM (RBP-Jκ associated molecule)
domain, ankyrin repeats flanked by nuclear localization sequences, a transactivation
domain (TAD, in Notch1 and Notch2 only), and a proline-glutamate-serine-threonine
(PEST) rich domain. B) Canonical Notch pathway regulation of transcription. After
cleavage by the γ-secretase complex, NICD translocates to the nucleus where it associates
with RPBP-Jκ. The RBP-Jκ-NICD complex then associates with mastermind-like protein
(MAML), causing the release of transcriptional repressors and the recruitment of coactivators, leading to active transcription of Notch effectors, including Hes and Hey
family members. Hes and Hey family members are basic helix-loop-helix transcription
factors which then regulate expression of downstream Notch targets.
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Notch in the vascular system
Notch signaling contributes to several processes during vascular development
including early differentiation between blood cell/endothelial cell progenitors and vSMC
progenitors, control of blood vessel sprouting, and arteriovenous fate specification 38,39.
The important role for Notch in differentiating between blood cell/endothelial cell
progenitors and vSMC progenitors during early extraembryonic mesoderm differentiation
was demonstrated by a series of elegant experiments in chick and quail embryos.
Extraembryonic mesodermal cells electroporated with NICD1 differentiated exclusively
into smooth muscle progenitor cells, and conversely, Notch inhibition by γ-secretase
inhibitors significantly reduced the number of smooth muscle progenitor cells, indicating
that Notch pushes the pluripotent progenitors towards a smooth muscle cell fate20.
The essential roles of Notch signaling during vascular formation are most
apparent in Notch knockout mouse models. For example, Notch 1-/- is embryonically
lethal. A primary vascular plexus is formed in the mutants, but fails to remodel into large
and small blood vessels. The abnormal vascular phenotype includes a reduction in arterial
marker expression by endothelial cells, indicating a role for Notch1 in arterial fate
specification 40. Notch 1 and Notch 4 appear to have some redundant function; deletion of
Notch 4 alone produces viable, normal adult mice and Notch 1-/- Notch 4-/- double
knockout mice have only slightly more severe defects than Notch1-/- mutants. Phenotypic
variations indicative of impaired vascular remodeling were apparent in both Notch1-/- and
Notch1-/-Notch4-/- mutants. Malformed large blood vessels in the anterior of the embryo
are apparent in both mutants 40. Jagged 1 null mutants are also embryonic lethal due to
vascular remodeling defects. Jag1-/- mice display severe hemorrhaging and a lack of large
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blood vessels by day E10.5 and are either completely resorbed or necrotic by day E11.5
41

.
Several groups have demonstrated an essential role for Notch during

pericyte/vSMC development. However, much of the data is conflicting and difficult to
interpret. In vitro, Notch has been shown to both promote and inhibit pericyte/vSMC
differentiation. The variation in reports may be due to the fact that individual studies
stimulated or mimicked Notch signaling differently (some used NICD transfection while
others used ligand stimulation), used different cell types as pericyte/vSMC models, and
defined vSMC differentiation using different markers 42-45. More recent studies using in
vivo manipulations of Notch indicate a necessity for Notch during pericyte/vSMC
differentiation. For example, when the Notch inhibitor dominant negative Mastermind
(DNMAM) was genetically introduced into neural crest cells (the pericyte/vSMC
progenitor of the cardiac outflow tract), mice displayed defective aortic arch patterning
due to an inability of neural crest cells to differentiate into vSMC 46. Additionally,
DLL4+/- mice and mice with endothelial cell specific deletion of Jagged 1 display reduced
numbers of α-SMA+ cells 47,48.
The role for Notch in vasculogenesis during development indicates that Notch
may also be involved in vascular formation in adults. DLL1, for example, plays an
important role during postnatal blood vessel formation. DLL1+/- mice subjected to
hindlimb ischemia had severely impaired artery formation, indicating a necessity for
DLL1 in artery regrowth in adults 49. Several Notch ligands and receptors are present in
the adult vascular system. To date, endothelial cell expression of Notch 1 and Notch 4 as
well as Jagged 1,2 and DLL1,4 has been demonstrated. Pericytes/vSMC are known to
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express Jagged 1, Notch 2 and Notch 3 39. We have shown that pericytes/vSMC also
express DLL4 in Ewing’s sarcoma 31. Expression of the other Notch receptors and
ligands by endothelial cells and pericytes/vSMC is probable; further exploration of Notch
in these cell types is needed.
The dramatic vascular defects observed in the above described Notch mutant mice
provide evidence for the key role of Notch in vascular development, and the presence of
Notch family members on cells of mature blood vessels indicates that Notch may be
important for vascular maintenance in adults. Our interest is in the role of Notch
signaling during blood vessel formation in tumors, specifically Ewing’s sarcoma. In
regard to tumor vascular development, perhaps the most well studied and critical Notch
family member is DLL4, described in detail below.
DLL4 plays a critical role in blood vessel development
DLL4 is essential for proper vessel formation. Vascular development is so
exquisitely sensitive to DLL4 dosage that even DLL4 heterozygosity causes embryonic
lethality in most mouse genetic backgrounds due to “profound vascular defects” 50,51.
DLL4 is highly expressed by the endothelium of large arteries during embryogenesis and
is expressed at low levels by smaller arteries and microvessels in adult mice, particularly
in tissues with active angiogenesis. DLL4 expression is increased, for example, in the
vasculature of maturing follicles of ovaries in sexually mature mice during ovulation 50.
While VEGF stimulates vessel branching and endothelial cell proliferation,
DLL4-Notch signaling inhibits these processes. Specifically, DLL4-Notch1 signaling
regulates endothelial tip vs stalk cell identity 52,53. Tip cells are specialized endothelial
cells at the leading front of growing vessels with increased migratory capacity. Tip cells
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extend filopodia and determine the direction of vessel growth. Stalk cells make up the
length of the vessel and generally do not extend filipodia. In normal mouse retinas, DLL4
is expressed by tip cells while Notch1 is expressed by stalk cells, and cells with active
Notch1 preferentially assume a stalk cell phenotype. Genetic or pharmacologic inhibition
of either DLL4 or Notch1 causes increased numbers of tip cells throughout the blood
vessels of mouse retinas and hindbrains. Endothelial cells in all parts of the vessel,
including the stalk, begin to extend filopodia and proliferate, leading to excessive vessel
branching and disorganization 52,53. DLL4 is therefore important for the formation of a
mature blood vessel network.
In addition to being expressed by endothelial cells during active vascular growth
or remodeling in physiologic conditions, DLL4 is highly expressed in the vasculature of
solid tumors, a hallmark of which is angiogenic growth 54. Increased expression of DLL4
by tumor endothelium compared to the endothelium of surrounding normal tissue has
been reported in several tumor xenograft models, including lymphoma, breast, colon, and
lung cancer 55,56. High DLL4 expression has also been identified in human patient
samples, including renal clear cell carcinoma and colon cancer 55,57.
Similar to the effect of DLL4 inhibition on mouse retinal blood vessel
development, DLL4 inhibition in tumors leads to increased microvessel proliferation, but
a paradoxical decrease in vessel functionality as assessed by vessel perfusion and hypoxia
within the tumor 56,58. Gliomas, for example, in mice treated with DLL4-Fc, a soluble and
therefore dominant negative form of DLL4, had increased endothelial cell density but
unorganized, non-perfuse vessels 58.
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A possible role of DLL4 in pericyte/vSMC formation during vascular maturation
is supported by the observation that in either mouse retinas or xenograft tumor models
where DLL4 is inhibited, there is a decrease in number of α-SMA+ cells surrounding
endothelial cells 59. Additionally, in human bladder cancer, DLL4 expression correlates
with vessel maturation. In a study of 60 human bladder cancer samples, Patel et al. found
that 98.7% of DLL4-positive tumor vessels co-expressed α-SMA, while only 64.5% of
DLL4-negative tumor vessels were associated with α-SMA+ cells 60.
The correlation between DLL4 expression and α-SMA expression implies that
DLL4 may be important for the formation of pericytes/vSMC. Also, DLL4 is highly
expressed by growing tumor vessels but is expressed at low levels on quiescent vessels.
Further, VEGF, which is highly expressed in Ewing’s sarcoma, positively regulates
DLL4 expression. When stimulated by VEGF, VEGF Receptor 2 induces increased
expression of DLL4 in a cell autonomous manner 61. We would therefore expect Ewing’s
sarcoma vessels, which are rapidly growing in a VEGF rich environment, to express
DLL4. Taken together, this makes DLL4 an attractive candidate as a key molecular
regulator of tumor vascular formation in Ewing’s sarcoma.
Studies of the role of DLL4 during blood vessel formation have thus far focused
on DLL4-Notch regulation of endothelial cell sprouting, an angiogenic process. Whether
DLL4-Notch signaling is also important in vasculogenesis, specifically in the
differentiation of BM-derived progenitor cells into pericytes/vSMC, is still unknown. We
have demonstrated that the blood vessels in Ewing’s sarcoma are formed by a
combination of vasculogenesis and angiogenesis, that vasculogenesis is essential for
tumor growth, and that BM cells contribute to the pericyte/vSMC population of most

20

vessels in Ewing’s sarcoma tumors 62,63. Ewing’s sarcoma is therefore a unique model for
the study of the role of DLL4 in vasculogenesis.
Hypothesis
Considering the following:
–

Notch receptors are expressed by BM cells and Notch signaling is necessary
for vSMC differentiation from neural crest progenitors

–

DLL4 is expressed by growing vessels, including tumor blood vessels

–

DLL4 is essential for the formation of mature, functional blood vessels

–

DLL4 expression correlates with α-SMA+ cell coverage of the endothelial
layer in several tumor models

The research presented in this dissertation was guided by the hypothesis that DLL4Notch signaling plays an important role in the formation of BM-derived
pericytes/vSMC in Ewing’s sarcoma. Specifically, we hypothesized that DLL4
stimulates Notch on incoming BM cells and activates pericyte/vSMC maturation
pathways.
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Chapter 2.
DLL4 is expressed by bone marrow derived pericytes/vascular smooth muscle cells
in Ewing’s sarcoma
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RATIONALE
We have previously demonstrated that a large portion of the pericytes/vSMC in
Ewing’s sarcoma are BM-derived 29,30. Additionally, we have demonstrated that while
most Ewing’s sarcoma tumor vessels have BM-derived perivascular cells, some do not.
The molecular mechanisms directing incoming BM progenitor cells to participate in
vascular formation and differentiate into pericytes/vSMC in some vessels but not others
are unknown. Understanding how BM-derived pericytes/vSMC are formed in Ewing’s
sarcoma may identify new targets to inhibit vasculogenesis and ultimately inhibit tumor
growth.
DLL4 plays an important role in tumor vessel development in several types of
solid tumors, including melanoma, breast, and colon cancer. It is selectively expressed by
endothelial cells of growing vessels as opposed to established, quiescent vessels. DLL4
expression by endothelial cells in tumors has functional significance; when DLL4 is
inhibited, tumor vessels are less organized with reduced perfusion and decreased pericyte
coverage 47,64,65. The high expression of DLL4 by growing vessels together with loss of
pericyte coverage after DLL4 inhibition indicates that DLL4 may play a role in the
formation of BM-derived pericytes/vSMC.
Prior to this dissertation research, DLL4/Notch signaling had not yet been studied
in Ewing’s sarcoma. We therefore examined DLL4 expression in Ewing’s sarcoma
patient samples and xenograft models. Based on reports of DLL4 expression by
endothelial cells in other tumor types, we expected to see CD31+DLL4+ endothelial cells
surrounded by GFP+ BM-derived pericytes/vSMC. We initially hypothesized that that
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DLL4 expressed by endothelial cells signals incoming BM cells to adhere and participate
in vascular formation.
In this chapter, immunohistochemical analysis was used to confirm the BM origin of
pericytes/vSMC and determine which cell types, if any, express DLL4 in Ewing’s
sarcoma.
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RESULTS
12 out of 14 patient samples are DLL4+
To determine whether DLL4 is present in Ewing’s sarcoma, we first obtained fourteen
patient samples and performed immunohistochemistry to evaluate DLL4 expression.
These included both primary and metastatic tumor samples from a total of ten patients.
Tumors were scored in a qualitative manner; 12 of 14 had DLL4+ regions (Figure 3). The
majority of DLL4+ cells in the patient samples were in thick layers surrounding the
vasculature. The perivascular location of these DLL4+ cells suggests that they may be
pericytes/vSMC. We were unable to confirm the pericyte/vSMC identity of the DLL4+
cells because these samples are paraffin embedded and therefore multi-color fluorescence
immunohistochemistry could not be performed. A few DLL4+ cells were also dispersed
in the mass of the tumor.
A

20x

20x

10x

B

Figure 3. DLL4 is expressed by perivascular cells in human Ewing’s sarcoma
samples. A) Immunohistochemistry was performed on 14 patient samples to examine
DLL4 expression. Brown cells are DLL4+.B) Hematoxylin and Eosin staining was
performed to examine the histology of the tumor sections and to identify blood vessels.
Magnification is indicated in white boxes. This figure was originally published in
Clinical Cancer Research, February 201066.
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TC71 and A4573 Ewing’s sarcoma xenograft models mimic the DLL4 expression
pattern of patient tumors
To confirm that our xenograft models effectively recapitulate the DLL4
expression pattern observed in the patient tumor specimens, we performed
immunohistochemistry for DLL4 on TC71 and A4573 tumor sections. Nude mice
received GFP BM transplants. Engraftment was confirmed one month later. Mice were
then injected subcutaneously with either TC71 or A4573 human Ewing’s sarcoma cells.
Tumors were allowed to grow to 2 cm3 before mice were sacrificed and tumors were
harvested and frozen for immunohistochemical evaluation. Tumor sections were costained for DLL4 and the endothelial cell marker CD31.
Similar to our findings using patient samples, several thick layers of DLL4+ cells
surrounded CD31+ endothelial cells (Figure 4). A few CD31+DLL4+ endothelial cells
were also observed in a small portion of the vessels.

A

B

Figure 4. DLL4 is expressed by perivascular cells in TC71 and A4573 Ewing’s
sarcoma tumors. (A) TC71 or (B) A4573 cells were implanted subcutaneously in nude
mice that had received a GFP BM transplant one month prior to tumor cell injection.
Three weeks later, tumors were removed and examined by immunohistochemistry for
CD31, to identify endothelial cells (green) and DLL4 (red). CD31 and DLL4 double
positive cells are yellow. 20x magnification.
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DLL4 expression by perivascular cells is confirmed by a second antibody
Prior to our work, DLL4 expression by non-endothelial cells had not been
previously reported. We therefore wished to confirm that the observed DLL4 expression
by perivascular cells in Ewing’s sarcoma was not an artifact of non-specific antibody
binding during immunohistochemistry. We again performed immunohistochemistry
against DLL4, using both the original antibody and a second anti-DLL4 antibody. With
both antibodies, a thick layer of perivascular cells expressing DLL4 was observed (Figure
5).

A

B

Figure 5. DLL4 expression by perivascular cells is confirmed by two antibodies.
TC71 cells were implanted subcutaneously in nude mice and allowed to form tumors.
Tumors were then examined by immunohistochemistry for endothelial cells using antiCD31 (green) and (A) Abcam anti-DLL4 (red) or (B) Cell Signaling Technology AntiDLL4 (red). 20x magnification.

DLL4 co-localizes with pericyte/vSMC markers
The peri-endothelial location of DLL4+ cells suggests that they may be
pericytes/vSMC. We performed immunohistochemistry for DLL4 in combination with
the pericyte/vSMC markers desmin and α-SMA on TC71 and A4573 tumors. DLL4 co-
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localizes extensively with desmin and with α-SMA (Figure 6), suggesting that the
majority of perivascular DLL4+ cells are pericytes/vSMC. In the DLL4 and desmin
double stained tumors, several desmin+DLL4- were also present. Additionally, in the
DLL4/α-SMA double stained tumors, several DLL4+/α-SMA- cells were present, as well
as α-SMA+/DLL4-. This indicates that not all pericytes/vSMC within the tumor express
DLL4.

DLL4 / desmin

DLL4 / α-SMA

Figure 6. DLL4 co-localizes with the pericyte/vSMC markers desmin and α-SMA.
Immunohistochemistry was performed on TC71 xenograft tumor sections to examine
expression of A) DLL4 (red) and the pericyte/vSMC marker desmin (green) or B) DLL4
(green) and α-SMA (red). In both panels, double positive cells are orange or yellow
(arrows indicate double positive cells).

DLL4+ pericytes/vSMC are BM-derived
The large network of perivascular DLL4+ cells was strikingly similar to the
pattern of GFP+ BM-derived pericytes/vSMC previously described 29. We first confirmed
our earlier finding that many of the pericytes/vSMC in Ewing’s sarcoma are BM-derived
by co-staining for GFP and desmin or α-SMA (Figure 7).
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To determine whether the DLL4+ pericytes/vSMC were themselves BM-derived,
we performed co-staining for DLL4 and GFP. The majority of DLL4+ perivascular cells
were also GFP+ (greater than 90%, Figure 8). Taken together with the finding that GFP
and DLL4 both co-localize with pericyte markers, we conclude that DLL4 is expressed
by BM-derived pericytes/vSMCs.

GFP / CD31

GFP / Desmin

GFP / α−SMA

Figure 7. GFP+ BM-derived cells express desmin and α-SMA. TC71 cells were
subcutaneously implanted in nude mice that had previously received a GFP BM
transplant. When tumors reached 2cm3, they were harvested, frozen and sectioned for
immunohistochemistry. Immunohistochemistry was performed using antibodies against
A) GFP (green), to identify BM-derived cells, and CD31 (red), to identify endothelial
cells, B) GFP (green), to identify BM-derived cells and desmin (red), to identify
pericytes/vSMC, and C) GFP (green), to identify BM-derived cells and α-SMA (red) to
identify pericytes/vSMC. Double positive cells are yellow or orange (arrows show double
positive cells).
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A

B

CD31 / DLL4

GFP / CD31

C

GFP / DLL4

Figure 8. DLL4+ cells in Ewing’s sarcoma are BM-derived. TC71 cells were
subcutaneously implanted in nude mice that had previously received a GFP BM
transplant. When tumors reached 2cm3, they were harvested, frozen and sectioned for
immunohistochemistry. Immunohistochemistry was performed using antibodies against
A) DLL4 (red) and CD31 (green), to identify endothelial cells, B) GFP (green), to
identify BM-derived cells and CD31 (red), to identify endothelial cells, and C) GFP
(green) to identify BM-derived cells and DLL4 (red). Double positive cells are yellow or
orange (arrows show double positive cells). 20x magnification.

RT-PCR confirms DLL4 expression by BM-derived cells
To determine whether DLL4 is expressed by BM-derived cells before they reach
the tumor, we used RT-PCR to examine DLL4 expression. Whole mouse BM was
isolated from mouse femurs and fluorescent activated cell sorting (FACS) was used to
collect Flk1+Sca1+ and Sca1+Gr1+ BM cell subpopulations. These subpopulations were
chosen because they were previously shown to differentiate into pericytes/vSMC in
Ewing’s sarcoma 63. RNA was collected from the whole BM as well as the two
subpopulations and RT-PCR for DLL4 was performed. DLL4 mRNA was present in
whole BM as well as both sub-populations, indicating DLL4 expression by each of the
three BM populations prior to migration to the tumor and participation in vasculogenesis
(Figure 9).
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We next confirmed our finding of DLL4 expression by GFP+ BM-derived cells
within the tumor. To this end, we again implanted TC71 cells subcutaneously in nude
mice that had previously received a GFP BM transplant and allowed tumors to grow until
they reached 2cm3. Tumors were then harvested and homogenized to obtain a single cell
suspension, and GFP+ BM-derived cells from within TC71 tumors were collected by
FACS. RNA was isolated, and RT-PCR was performed to look at DLL4 expression. In
agreement with previous immunohistochemical findings, DLL4 mRNA is present in

H2O
Negative

Sca1+Gr1+

Flk1+Sca1+

Whole BM

GFP+ BM-derived cells isolated from TC71 tumors (Figure 10).

DLL4
GAPDH

H20 negative

GFP+ from tumor

Figure 9. Whole BM, Flk1+Sca1+, and Sca1+Gr1+ BM subpopulations express DLL4.
Whole BM was collected from nude mice, and Flk1+Sca1+ or Sca1+Gr1+ subpopulations
were isolated by FACS. RNA was collected from whole BM and both subpopulations,
and RT-PCR for DLL4 was performed.

DLL4
GAPDH

Figure 10. GFP+ BM-derived cells isolated
from TC71 tumors express DLL4 mRNA.
TC71 cells were subcutaneously implanted
in nude mice that had previously received
GFP BM transplants and tumors were
allowed to form. Tumors were homogenized
and GFP+ BM-derived cells were collected
by FACS. RNA was collected from GFP+
BM-derived cells, and RT-PCR for DLL4
was performed.

31

The majority of BM-derived cells are not fibroblasts
Due to the extensive number of GFP+ BM-derived perivascular cells, it seemed likely that
some of the BM-derived cells were a cell type other than pericytes/vSMC. Fibroblasts are
non-tumor derived infiltrating cells within tumors and can express desmin and PDGFRβ67. We therefore considered the possibility that a portion of the perivascular BM-derived
cells within the tumor are fibroblasts. To this end, we performed immunohistochemistry
for the fibroblast marker S100A4 in conjunction with CD31 or GFP. S100A4+ cells were
observed in small regions throughout the tumor, including in some perivascular locations
adjacent to CD31 (Figure 11a). However, only a small portion of vessels had S100A4+
cells in the perivascular region and the majority of GFP+ BM-derived cells were did not
express S100A4 (Figure 11b,c).
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A

S100A4 green/ CD31

B

S100A4 green/ CD31

GFP green/ CD31 red

C

GFP green/ S100A4 red

Figure 11. The majority of BM-derived cells are not fibroblasts. TC71 cells were
implanted subcutaneously in nude mice that had previously received GFP BM
transplants. Tumors were harvested and examined by immunohistochemistry for A)
S100A4, to identify fibroblasts (green) and CD31, to identify endothelial cells (red), 10x
magnification. B) Immunohistochemistry was performed for either S100A4 (green) and
CD31 (red) or GFP, to identify BM-derived cells (green), and CD31 (red). The same
vessel was located and photographed on adjacent tumor sections. 20x magnification. C)
Co-staining for GFP (green), to identify BM-derived cells, and S100A4 (red), to identify
fibroblasts, was performed. BM-derived fibroblasts are double positive and are orange
(arrow indicates BM-derived fibroblast). 10x magnification.
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SUMMARY
Contrary to our initial hypothesis, DLL4 is highly expressed by the perivascular
cells and only rarely by endothelial cells in Ewing’s sarcoma. This was demonstrated in
both patient samples and xenograft models. It is unlikely that the observed DLL4
expression by perivascular cells is an artifact of a nonspecific antibody used for
immunohistochemistry, because it was further confirmed using a second anti-DLL4
antibody. The majority of DLL4+ cells in Ewing’s sarcoma vasculature are
pericytes/vSMC. This was shown by immunohistochemistry, which was used to
demonstrate co-localization of DLL4 with the pericyte/vSMC markers desmin and αSMA.
We are the first to report DLL4 expression by predominantly pericytes/vSMC in a
tumor model. Recent reports of DLL4 expression by non-endothelial cells corroborate
our initial findings. Indracollo et el. have reported the presence of DLL4+/CD31- cells
within MICOL-14 T-ALL xenograft tumors. Our findings are unique in that we show that
the DLL4+ cells are pericytes/vSMC in Ewing’s sarcoma and are BM-derived. A GFP
BM transplant model was used to confirm our previous finding that the pericytes/vSMC
in Ewing’s sarcoma tumors are a mosaic of locally and BM-derived cells. The similar
perivascular pattern of GFP+ BM-derived cells and DLL4+ cells, together with the fact
that both GFP and DLL4 are expressed by desmin+ and α-SMA+ pericytes/vSMC,
suggested that the DLL4+ cells are themselves BM-derived. This was confirmed by costaining for GFP and DLL4, which revealed greater than 90% co-localization.
RT-PCR for DLL4 demonstrated that DLL4 mRNA is present in whole BM from
the mouse femur as well as the Flk1+Sca1+ and Sca1+Gr1+ subpopulations. Additionally,
DLL4 mRNA was present in GFP+ BM-derived cells isolated directly from TC71 tumors.
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This confirms our immunohistochemical data indicating that BM-derived perivascular
cells are DLL4+.
In light of the findings presented in this chapter, our initial hypothesis, that DLL4
expressed by endothelial cells signals to incoming BM cells and directs them to adhere
and/or differentiate into pericytes/vSMC, was modified. While this may be true to a small
extent (a few DLL4+ endothelial cells were observed in the Ewing’s sarcoma xenograft
models), we concluded that the majority of DLL4+ cells are BM-derived pericytes/vSMC.
With this in mind, we hypothesized that DLL4 expressed by one perivascular BMderived cell activates Notch receptors on neighboring BM cells and vice versa. We
further hypothesized that this DLL4-Notch signaling plays an important role in BM
cell participation in vasculogenesis and differentiation into pericytes/vSMC.

35

Chapter 3.
Notch signaling is required for bone marrow cell participation in vascular
formation
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RATIONALE
The surprising discovery that DLL4 is expressed by BM-derived pericytes/vSMC
in Ewing’s sarcoma led to the hypothesis that DLL4 on perivascular BM-derived cells
activates Notch signaling in surrounding BM cells, and that this DLL4-Notch signaling is
critical for maturation of BM-derived progenitor cells into pericytes/vSMC. If this
hypothesis is correct, and DLL4-Notch signaling plays an important role in the formation
of BM-derived pericytes/vSMC, then active Notch signaling in BM-derived cells within
the tumor should be evident. Additionally, if Notch signaling is essential for the BMderived cells to become pericytes/vSMC within the tumor, then inhibition of Notch
signaling within incoming BM cells should prevent them from becoming a part of the
perivascular layer in tumor vasculature. Since we demonstrated that the majority of the
pericytes were BM-derived, the inhibition of Notch signal should result in a significant
decrease in the number of pericytes/vSMC.
In this chapter, we first looked for evidence of active Notch signaling within BMderived cells of Ewing’s tumor vasculature. Immunohistochemistry was used to examine
the localization of cleaved Notch 1, an indicator of activated Notch. As a second indicator
of Notch signaling activity, GFP+ BM-derived cells were isolated directly from TC71
tumors and RT-PCR was performed to look at the expression of downstream Notch
effectors.
To determine whether active Notch in BM cells has functional significance during
vasculogenesis, Dominant Negative Mastermind (DNMAM) was used to inhibit the
ability of BM cells to receive the Notch signal. BM cells with inhibited Notch function
were then assessed for their ability to participate in tumor vascular formation.
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RESULTS
Cleaved Notch1 is in a similar perivascular location to GFP and DLL4
When Notch receptors are activated, the intracellular domain is cleaved and
translocates to the nucleus. We therefore used an antibody specific for the Notch1
intracellular domain (NICD1) to look for evidence of Notch receptor activation by
immunohistochemistry. Sequential sections of TC71 tumors from mice that had
previously received GFP BM transplants were examined by immunohistochemistry for
CD31 in combination with GFP, NICD1, or DLL4. The same vessel on each slide was
located and photographed. GFP+ BM-derived cells, NICD1+ cells, and DLL4+ cells all
form perivascular layers surrounding CD31+ cells. As shown in figure 12, the pattern of
GFP, NICD1, and DLL4 expression is similar, implying that Notch 1 is activated in
GFP+DLL4+ BM-derived perivascular cells. Triple color staining could not be performed
due to the limitations of our microscope equipment.

NICD1 – green
CD31-red

GFP- green
CD31- red

DLL4- green
CD31- red

Figure 12. NICD1, GFP, and DLL4 are expressed in a similar pattern by
perivascular cells in TC71 tumors. TC71 cells were implanted in GFP BM-transplanted
nude mice and allowed to form tumors. Tumors were then harvested and
immunohistochemistry was performed on adjacent frozen sections to examine CD31
(red), to identify endothelial cells, in combination with A) NICD1 (green), to identify
active Notch 1 B) GFP (green), to identify BM-derived cells C) DLL4 (green). 20x
magnification.
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Notch signaling is active in BM-derived cells within the tumor
To gain further evidence that Notch signaling is active in GFP+ BM-derived cells
within the tumor, we again harvested TC71 tumors from nude mice that had previously
received a GFP BM transplant. Tumors were homogenized until single cell suspension
was achieved. GFP+ cells were collected by FACS, and RNA was collected from these
GFP+ BM-derived cells. RT-PCR was performed to look at expression of the Notch
effector Hes1 as a surrogate marker of active Notch signaling. Hes1 was expressed in
GFP+ cells collected from TC71 tumors (Figure 13). Real time PCR was then used to
confirm the presence of the Notch effectors Hey1 and Hey2 in the GFP+ BM-derived
cells (data not shown). Hes1, Hey1, and Hey2 were each present, indicating that the

H2O negative

GFP+ from tumor

Notch pathway is active in BM-derived cells within the tumor.

Hes 1
GAPDH

Figure 13. Notch effector Hes1 is expressed in BM-derived cells within Ewing’s
sarcoma tumors. TC71 cells were subcutaneously implanted in GFP BM-transplanted
nude mice and allowed to form tumors. When tumors reached 2cm3, they were harvested
and digested into a single cell suspension. GFP+ BM-derived cells from within the tumor
were collected by FACS, and RNA was isolated, and RT-PCR was performed for the
Notch effector Hes1.
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Notch signaling is necessary for BM cells to become pericytes/vSMC in Ewing’s
sarcoma
After confirming that Notch is active in BM-derived cells within Ewing’s
sarcoma tumors, we wished to determine whether Notch signaling is necessary for BM
cell participation in vasculogenesis in Ewing’s sarcoma. As depicted in figure 14, nude
mouse BM cells were transduced with retroviral MigR1 containing dominant negative
mastermind (MigR1-GFP/DNMAM) or MigR1-GFP control. DNMAM inhibits
canonical Notch signaling by preventing the formation of the NICD/RBP-Jk/MAML
transcriptional activating complex. MigR1-GFP/DNMAM induces expression of a
DNMAM-GFP fusion protein; transduced cells can be tracked by GFP expression. 48
hours after transduction of BM cells, GFP+ cells from both groups (MigR1GFP/DNMAM and MigR1-GFP control) were collected and BM transplants were
performed on nude mice. Recipients were given either MigR1-GFP/DNMAM BM or
MigR1-GFP. One month after transplant, TC71 cells were injected subcutaneously.
Tumor growth was followed for 2 weeks before mice were sacrificed and tumors were
harvested for immunohistochemical analysis. While several perivascular GFP+ cells were
observed in tumors from MigR1-GFP control mice, there were very few perivascular
GFP+ cells in tumors from MigR1-GFP/DNMAM transplanted mice (Figure 15).
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Collect nude mouse BM
Transduce nude mouse BM
with MigR1-GFP or MigR1GFP/DNMAM
48 hours

Sort for GFP+ BM
GFP BMT
a) MigR1-GFP control BM
b) MigR1-GFP/DNMAM BM
1 month

Inject TC71 subcutaneously
2 weeks

Sacrifice mice, remove tumors

Figure 14. Schematic diagram of MigR1-GFP/DNMAM experimental design. Nude
mouse BM was be collected from femurs and immediately transduced with MigR1-GFP
or MigR1-GFP/DNMAM. Transduced BM was cultured in vitro for 48 hours, and then
GFP+ (transduced) cells were collected by FACS. BM transplants were then performed on
nude mice, where recipients were given either MigR1-GFP or MigR1-GFP/DNMAM
BM. After BM engraftment, mice were injected subcutaneously with TC71 cells. Tumors
were allowed to grow for two weeks before mice were sacrificed and tumors were
harvested.
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A

B

Figure 15. GFP+ BM-derived cells are reduced in tumors in mice that received
MigR1-GFP/DNMAM BM transplants compared to control. Nude mouse BM cells
were transduced with A) MigR1-GFP or B) MigR1-GFP/DNMAM and transplanted into
recipient mice. TC71 cells were injected subcutaneously and allowed to form tumors.
Two weeks later, tumors were harvested and examined by immunohistochemistry for the
presence of GFP+ BM-derived cells (green) and CD31+ endothelial cells (red). Nuclei are
blue. 20x magnification.

Additionally, there was a trend towards smaller tumors in mice that had received
MigR1-GFP/DNMAM transplants compared to control (data not shown). The trend
towards smaller tumors in the MigR1-GFP/DNMAM mice compared to MigR1-GFP
implies that tumors in MigR1-GFP/DNMAM mice may have regions undergoing
apoptosis. To determine whether this was in fact the case, immunohistochemistry for
TUNEL was performed to identify apoptotic cells. TUNEL+ regions were larger and
more frequent in the tumors from MigR1-GFP/DNMAM transplanted mice compared to
control (Figure 16).
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Figure 16. Apoptosis is increased in tumors from MigR1-GFP/DNMAM BMtransplanted mice compared to tumors in MigR1-GFP control BM-transplanted
mice. Nude mouse BM cells were transduced with MigR1-GFP or MigR1GFP/DNMAM and transplanted into recipient mice. TC71 cells were injected
subcutaneously and allowed to form tumors. Two weeks later, tumors were harvested and
examined by immunohistochemistry for the presence of TUNEL to identify apoptotic
cells (green). Nuclei are blue. 20x magnification.
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SUMMARY
In support of our hypothesis that Notch signaling is activated in incoming BMderived cells, NICD1 (cleaved Notch1) was detected by immunohistochemistry in the
perivascular cells surrounding CD31+ endothelial cells. This pattern of NICD1 was
consistent with the pattern of GFP+ BM-derived cells and DLL4+ cells surrounding the
same CD31+ vessel on serial tumor sections. However, because we are unable at this time
to use triple color immunohistochemistry, a definitive demonstration of NICD1 in
perivascular GFP+ BM-derived cells cannot be obtained. Therefore, to validate these
findings, RT-PCR was used.
GFP+ BM-derived cells were isolated from TC71 tumors, RNA was collected, and
RT-PCR performed. RT-PCR and real time PCR for the Notch effectors Hes1, Hey1, and
Hey2 revealed expression of all three. This indicates active Notch signaling within BMderived cells after the cells reach the tumor and participate in vascular formation.
After demonstrating that Notch signaling is active in BM-derived cells within the
tumor, we used DNMAM to demonstrate that Notch signaling in these cells is necessary
for their participation in vascular formation. TC71 tumor cells were subcutaneously
injected in mice that had received BM transplants of either MigR1-GFP control BM or
MigR1-GFP/DNMAM BM. As expected, thick layers of perivascular GFP+ BM-derived
cells were observed in tumors from mice transplanted with MigR1-GFP control BM.
However, in tumors from mice that had received MigR1-GFP/DNMAM BM transplants,
very few GFP+ BM-derived cells surrounded the vasculature. This indicates that Notch
signaling is critical for BM-derived cells to participate in formation of the perivascular
layer of blood vessels in Ewing’s sarcoma.
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Additionally, tumors from MigR1-GFP/DNMAM mice were smaller than their
control counterparts. We confirmed that large regions of the MigR1-GFP/DNMAM
tumors were undergoing apoptosis using TUNEL staining. This reduced tumor growth is
likely due to a decrease in blood vessel functionality caused by the loss of perivascular
BM-derived cells. However, to definitively attribute this decreased tumor growth and
increased tumor cell apoptosis to a change in vascular function, vessel perfusion and
hypoxia studies would need to be performed.
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Chapter 4.
DLL4 is critical for pericyte/vSMC formation in Ewing’s sarcoma in vivo

46

RATIONALE
Having established that DLL4 is expressed by BM-derived pericytes/vSMC and
that Notch signaling is activated and necessary in these BM-derived cells for their
participation in pericyte/vSMC formation, we next wished to determine whether DLL4 is
the Notch ligand responsible for activating Notch receptors on incoming BM cells. We
hypothesized that inhibition of DLL4 will inhibit the formation of BM-derived
pericytes/vSMC in Ewing’s sarcoma.
To determine whether DLL4 is necessary for BM-derived cells to contribute to
the pericyte/vSMC pool in tumor vasculature, we first wanted to inhibit DLL4 locally
within the tumor, but not systemically. When this research was initially begun, very little
was understood about the role of DLL4, if any, in immature BM-derived pericyte
progenitor cell maintenance. Systemic inhibition of DLL4 could potentially negatively
impact BM progenitor cell viability while they were still in the BM or in circulation,
before the cells ever reached tumor vasculature. A reduction in BM-derived perivascular
cells after systemic DLL4 inhibition would therefore be difficult to interpret because it
could be the result of two different possibilities. While the reduction might be due to
blocking DLL4-Notch signaling during BM maturation into pericyte/vSMCs, it may also
be due to BM progenitor cell death before the cells reached the tumor.
Therefore, to circumvent this obstacle, shRNA to inhibit DLL4 expression was
delivered directly to the tumor via intratumor injection. In this model, bilateral tumors in
the same mouse were injected with shDLL4 in the right side tumor and non-targeting shcontrol in the left side tumor. Since both tumors are in the same host, both tumors share
an identical BM progenitor pool. DLL4 expression is locally inhibited within the tumor
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but not in the BM. Any difference in the GFP+ BM-derived cell population seen within
the tumor can be attributed only to the inhibition of DLL4-Notch in BM cells after
migration to the tumor. We used shDLL4 to determine whether DLL4 is important for the
formation of BM-derived pericytes/vSMC.
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RESULTS
Intratumor PEI/shDLL4 inhibits expression of DLL4 on tumor vessels
We used intratumor injections of the nonviral vector polyethylenimine (PEI)
carrying shRNA against DLL4 (shDLL4) or a non-targeting shRNA control (sh- control)
to inhibit expression of DLL4 on tumor vasculature. As illustrated by the schematic in
figure 16, one month after GFP BM transplantation, nude mice were subcutaneously
injected with TC71 Ewing’s sarcoma cells on both the left and right flanks. When tumors
were palpable (day 4) intratumor injections of shDLL4 (right side) or sh- control (left
side) were begun, continuing every other day for 24 days. The final tumor volumes were
measured, mice were sacrificed, and tumors were harvested for evaluation by
immunohistochemistry.

GFP
BMT

Every other day:
Left: PEI/shRight: PEI/shDLL4

Bilateral
TC71
subcu

x
Day: -30

0

4

28

Figure 17. Experimental schema for intratumor injections of PEI/shDLL4 or
PEI/sh-control. Nude mice received GFP BM transplants and 30 days were allowed for
BM cell engraftment. TC71 cells were then injected bilaterally. When tumors became
palpable four days later, every other day intratumor injections were begun. Right side
tumors received PEI/shDLL4 and left side tumors received PEI/ sh- control. Mice were
sacrificed 28 days after injection of TC71 cells and tumors were harvested for
immunohistochemical evaluation.
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We first confirmed that DLL4 was inhibited following injection of PEI/shDLL4.
In tumors treated with PEI/shDLL4, DLL4 was dramatically reduced compared to control
(Figure 18a). In the PEI/shDLL4 treated tumors, very few DLL4+ cells were observed
surrounding the vessels.
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Sh- control

shDLL4

Sh- control

shDLL4

Red: DLL4
Green: CD31
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Figure 18. Loss of DLL4+ cells correlates with a reduction in GFP+ BM-derived cells
in TC71 tumors after treatment with PEI/shDLL4. TC71 cells were implanted
bilaterally in mice that had previously received a GFP BM transplant. When tumors were
palpable, every other day intratumor injections of PEI/shDLL4 (right side tumors) or
PEI/sh- control (left side tumors) were begun. 28 days after tumor inoculation, tumors
were harvested and examined by immunohistochemistry for A) DLL4 (red) and CD31
(green), to identify endothelial cells or B) GFP (green) to identify BM-derived cells and
CD31 (red) to identify endothelial cells. PEI/sh- control or PEI/shDLL4 treatment is
indicated in the top left of each photo. 20x magnification.
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Loss of DLL4 correlates with a loss of GFP+ BM-derived perivascular cells
After confirming loss of DLL4 in PEI/shDLL4 treated tumors, we next used
immunohistochemistry to determine whether the number of GFP+ BM-derived cells was
reduced. Similar to the reduction in DLL4+ cells, few or no GFP+ cells were observed
surrounding CD31+ endothelial cells in PEI/shDLL4 treated tumors compared to PEI/shcontrol (Figure 18b).

Loss of DLL4 correlates with a reduction in α-SMA+, NG2+, and desmin+
perivascular cells
To determine whether the loss of DLL4 and GFP+ BM-derived cells correlates
with an overall reduction in the number of pericytes/vSMC, we examined the expression
of α-SMA, desmin, and NG2. α-SMA expression was reduced by 91% (p <0.0001),
desmin by 57% ( p < 0.001), and NG2 by 43% (p: 0.08). Representative fields and
quantification data are shown in figure 19.
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Figure 19. The pericyte/vSMC markers α-SMA, desmin and NG2 are reduced in
shDLL4 treated tumors. TC71 cells were implanted bilaterally in GFP BM-transplanted
nude mice. Tumors were treated with intratumor injections of PEI/shDLL4 (right side
tumors) or PEI/sh- control (left side tumors) for 23 days. Tumors were then harvested and
examined for the presence of CD31 (green) to identify endothelial cells in combination
with α-SMA, desmin, or NG2 (red, indicated above each panel) to identify
pericytes/vSMC. The total positive pixels for each pericyte/vSMC marker was quantified
and the reduction in PEI/shDLL4 treated tumors compared to PEI/sh- control was
determined. Percent reduction and p-values are reported below each panel.

PEI/shDLL4 treated tumors have increased hypoxia
Without pericytes, vessel functionality may be compromised. To determine
whether the near complete loss of pericytes/vSMC in PEI/shDLL4 treated tumors
correlated with a reduction in vessel functionality, we examined hypoxia. Increased
hypoxia is a surrogate marker for reduced vessel function. Nude mice were again injected
with bilateral subcutaneous TC71 cells. As before, left side tumors were treated every
other day with intratumor injections of PEI/sh- control and right side tumors were treated
with PEI/shDLL4. Prior to sacrifice, mice were injected with Hypoxyprobe-1.
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Hypoxyprobe-1 forms pimonidazole adducts in hypoxic cells and can be recognized by
immunohistochemistry. Tumors were then harvested and evaluated for hypoxia. Hypoxia
was significantly increased in tumors treated with PEI/shDLL4 compared to control (p =
0.03, Figure 20), implying reduced supply of oxygenated blood to these tumors most
likely secondary to reduced vessel functionality.
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Figure 20. Hypoxia is increased in tumors treated with shDLL4 compared to shcontrol. TC71 cells were injected subcutaneously on both flanks of nude mice. Mice
were treated with intratumor injections of PEI/shDLL4 (right side tumors) or PEI/shcontrol (left side tumors). Prior to sacrifice, mice were injected i.v. with hypoxyprobe-1
(pimonidazole hydrochloride). Tumors were then removed and examined by
immunohistochemistry. A) Hypoxic cells were identified using an anti-hypoxyprobe-1
antibody (red/orange) and nuclei by sytox green (green). B) The hypoxia to nuclei ratio
was quantified for five 10x fields per tumor using SimplePCI software.
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Hoescht 33342 was an ineffective measure of vessel perfusion
To further explore the functionality of tumor blood vessels, we wished to measure the
number of vessels with blood flow compared to the total number of vessels present. To
do this, we used tail vein injections of Hoescht33342 dye immediately prior to sacrifice.
Hoescht33342 dyes the nuclei of any cell that it contacts blue; thus it can be used to track
the pattern of blood flow. Extensive blue labeling of cells distant from blood vessels in
tumors in both shDLL4 and sh- control groups made experimental results from
Hoescht33342 nuclei labeling difficult to interpret. We were unable to determine which
vessel the dye had leaked from, and therefore unable to distinguish perfused from nonperfused vessels. Hoescht 33342 studies were therefore inconclusive (data shown in
appendix).

shDLL4 inhibits tumor growth in vivo
The impaired vessel functionality in tumors treated with PEI/shDLL4 suggested
that tumor growth might also be inhibited. Tumor volume was measured immediately
before mice were sacrificed. As shown in figure 21, tumors treated with PEI/shDLL4
were significantly smaller (120 mm3) than those treated with PEI/sh- control (299 mm3, p
= 0.03). In mice where right side tumors were not smaller than left side tumors,
immunohistochemistry demonstrated that DLL4 expression was not significantly
inhibited (data not shown).
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Figure 21. shDLL4 inhibits TC71 tumor growth in vivo. Mice were injected with
bilateral subcutaneous TC71 cells. When tumors were palpable, every other day
intratumor injections of PEI/shDLL4 (right side tumors) or PEI/sh- control (left side
tumors) were begun. Two weeks later, final tumor volumes were measured and mice
were sacrificed. Tumor volumes are displayed as matched pairs of right and left side
tumors from the same mouse. Student’s paired t-test p-value = 0.03, * represents tumors
where DLL4 was not significantly inhibited after treatment with PEI/shDLL4
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SUMMARY
In this chapter, evidence of a critical role for DLL4 in BM-derived cell
participation in vasculogenesis in Ewing’s sarcoma is provided. The hypothesis that
inhibition of DLL4 will inhibit the formation of BM-derived pericytes/vSMC was
confirmed.
Intratumor injections of shDLL4 caused a dramatic reduction of DLL4 expression
by perivascular cells compared to sh- control tumors. Loss of DLL4 correlated with a
near complete loss of GFP+ BM-derived perivascular cells. This was shown by
immunohistochemistry for DLL4 or GFP together with CD31 (to identify endothelial
cells). The reduction in BM-derived perivascular cells after loss of DLL4 can be
attributed to an important role for DLL4-Notch signaling once BM cells reach the tumor.
This was confirmed by the use of a bilateral tumor model. In this model, sh- control
treated tumors and their shDLL4 treated counterparts shared the same BM progenitor cell
pool. Sh-control tumors displayed the expected thick layers of perivascular GFP+ BMderived cells, while shDLL4 treated tumors had almost no GFP+ BM-derived cells
present.
After identifying a role for DLL4 in the formation of the GFP+ BM-derived
perivascular cell layer, we next demonstrated that loss of DLL4 correlates with a
significant reduction in pericytes/vSMC within the tumor. α-SMA, desmin, and NG2
were all significantly reduced in tumors treated with shDLL4 compared to sh-control
treated tumors, as assessed by immunohistochemistry. This reduction in cells positive for
three pericyte/vSMC markers indicates an overall reduction in pericytes/vSMC after
DLL4 expression is inhibited.

56

The striking change in vascular phenotype after DLL4 inhibition is indicative of a
potential change in vessel functionality. Hypoxia was measured as a surrogate marker for
vessel functionality; increased hypoxia correlates with reduced vessel functionality.
Tumor hypoxia was increased in tumors treated with shDLL4 compared to control. This
increased hypoxia correlates with decreased pericyte coverage and agrees with previous
studies by Noguera-Troise et al. demonstrating increased tumor hypoxia in C6 gliomas in
mice after DLL4 inhibition 58.
Reduced pericyte coverage of blood vessels and subsequent reduced vessel
functionality in tumors treated with shDLL4 was expected to have a negative impact on
tumor growth. In agreement with this, tumors treated with shDLL4 were significantly
smaller than their sh- control treated counterparts.
These studies are the first to show the critical role of DLL4 in BM-derived
pericyte/vSMC differentiation and formation, and to demonstrate Ewing’s sarcoma tumor
growth inhibition caused by loss of DLL4. Inhibition of DLL4 resulted in fewer BMderived cells within the tumor. The tumor vessels had decreased pericyte/vSMC
coverage, were smaller, and less functional. Tumor growth was also inhibited. To further
confirm and expand these novel findings, we used a second, more elegant tool, the DLL4
neutralizing antibody YW152F, described in the next chapter.
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Chapter 5.
DLL4 blockade inhibits tumor growth by disrupting the formation of functional
vasculature
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RATIONALE
Previous DLL4 inhibition studies using shDLL4 demonstrated that DLL4 is
necessary for the formation of BM-derived pericytes/vSMC in Ewing’s sarcoma.
However, there are some limitations associated with using intratumor injections of
shRNA. First, equal distribution of shRNA (and therefore uniform DLL4 knockdown)
throughout the entire tumor is highly unlikely. Although immunohistochemical analysis
confirmed knockdown of DLL4 in the majority of vessels in tumors treated with
PEI/shDLL4, some DLL4 expression was still observed in small regions of treated
tumors and there were a small number of tumors where DLL4 expression was not
inhibited by shDLL4. Another limitation of the intratumor injection model is the lack of
clinical application. In general, shRNA is not stable enough to be delivered systemically
to patients and intratumor injections are not feasible.
Therefore, to confirm our findings, we elected to use a second approach to
demonstrate the essential role of DLL4 in pericyte/vSMC formation in Ewing’s sarcoma.
YW152F is a humanized DLL4-neutralizing antibody that binds to and inhibits the
function of both human and mouse DLL4 with similar efficiency and efficacy. It is an
attractive inhibitor of DLL4 because it can be delivered systemically via i.v. injection and
is highly specific for DLL4 but not the other Notch ligands. In addition to using YW152F
as a second tool to confirm our initial finding that DLL4 is essential for BM-derived
pericyte/vSMC formation, we also wished to determine whether DLL4 is a viable
therapeutic target for inhibiting the growth of Ewing’s sarcoma in vivo. For these
investigations, the two models discussed previously, TC71 and A4573, were used.
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Studies in this chapter confirmed our previous findings and expanded our
understanding of DLL4 inhibition as a way to inhibit Ewing’s sarcoma tumor growth.
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RESULTS
YW152F inhibits the growth of Ewing’s sarcoma in vivo
To confirm our previous finding that DLL4 is essential for vasculogenesis and tumor
growth in Ewing’s sarcoma, we used the DLL4-neutralizing antibody YW152F (Figure
22). One month after GFP BM transplant, mice were injected subcutaneously with either
TC71 or A4573 cells. Five days later, twice weekly tail vein injections of either
YW152F, IgG control, or PBS were begun. Twenty-one or 24 days after tumor
inoculation, final tumor volumes were measured before mice were sacrificed and tumors
were harvested for immunohistochemical analysis. TC71 tumors from mice treated with
YW152F were significantly smaller than tumors from mice treated with IgG or PBS
controls (p = 0.03, Figure 23). A4573 tumors from mice treated with YW152F were also
significantly smaller than those in mice treated with IgG control (p = 0.015, Figure 24).
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Figure 22. Experimental schema using YW152F, IgG or PBS. Twenty eight days
after GFP BM transplants were performed on nude mice, TC71 or A4573 cells were
injected subcutaneously. Five days later, twice weekly i.v. injections of either YW152F,
IgG or PBS were begun. Mice with TC71 tumors received a total of 5 treatments and
mice with A4573 tumors received a total of 6 treatments. 3 days after the last treatment,
tumors were measured, mice were sacrificed, and tumors were harvested.

61

p =0.7

A

p = 0.03

1600
1400

3

tumor volume (mm)

1200
1000
800
600
400
200
0

PBS

IgG

YW152F

B

YW152F
IgG
PBS

Figure 23. YW152F inhibits TC71 tumor growth in vivo. TC71 cells were
subcutaneously injected in nude mice that had previously received GFP BM transplants.
Mice were treated with either YW152F, IgG, or PBS. Final tumor volumes were
measured prior to sacrifice of mice, and statistical significance for the difference in size
was calculated using the student’s t-test. Tumors were then harvested for
immunohistochemical evaluation. A) Final tumor volumes. Orange diamonds represent
tumors from PBS treated mice, blue squares represent tumors from IgG treated mice, and
pink triangles represent tumors from YW152F treated mice. B) Resected tumors before
being frozen for immunohistochemistry. Treatment group is indicated to the left of the
photo.
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Figure 24. YW152F inhibits the growth of A4573 tumors in vivo. A4573 cells were
subcutaneously injected in nude mice that had previously received GFP BM transplants.
Mice were treated with YW152F or IgG. Final tumor volumes were measured prior to
sacrificing mice. A) Final tumor volumes. Blue diamonds represent tumors from IgG
treated mice and pink squares represent tumors from YW152F treated mice. B) Resected
tumors before being frozen for immunohistochemistry. Treatment group is indicated to
the left of the photo.
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YW152F does not effect cell proliferation in vitro
To determine whether the inhibition of tumor growth by YW152F was due to a
direct effect of the antibody on tumor cell proliferation, we treated TC71 and A4573 cells
with either YW152F or IgG control (5μg/ml, refreshed daily) in vitro. Total number of
viable cells was assessed using the trypan blue assay by a ViCell automated cell counter
at 48 and 72 hours. There was no significant difference between the number of viable
cells in YW152F treated wells compared to control at either dose or time point (Figure
25).
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Figure 25. YW152F does not inhibit tumor cell proliferation in vitro. A4573 or TC71
cells were treated with 5μg/ml YW152F or IgG, refreshed daily. Total number of viable
cells was measured using the trypan blue assay and automated ViCell counter at 48 and
72 hours. Blue bars represent IgG control treated cells, maroon represent YW152F
treated cells.
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GFP+, α-SMA+, NG2+, and desmin+ cells are reduced after YW152F treatment
After demonstrating that tumor growth inhibition by YW152F was not due to a
direct effect on tumor cell proliferation, we examined the vasculature for changes in the
number of BM-derived pericytes/vSMC. We first used immunohistochemistry to evaluate
TC71 tumors for the presence of GFP+ BM-derived cells. Similar to our findings using
shDLL4, the number of GFP+ BM cells was reduced in tumors from YW152F treated
mice compared to control (85% reduction, p= 0.001). We next examined the α-SMA+,
NG2+, and desmin+ populations of pericytes/vSMC by immunohistochemistry. As shown
in figure 26, the number of α-SMA+, NG2+, and desmin+ cells was significantly reduced
in YW152F treated tumors compared to control (α-SMA reduced 87%, p: 0.005; NG2
61%, p:0.007; desmin 70%, p:0.002).

65

α-SMA / CD31

NG2 / CD31 Desmin / CD31

YW152F

IgG

GFP / CD31

Figure 26. GFP, α-SMA, NG2 and desmin are significantly reduced in tumors after
YW152F treatment. TC71 cells were subcutaneously injected in nude mice that had
previously received GFP BM transplants. Mice were treated with either YW152F or IgG.
After mice were sacrificed and tumors were harvested, immunohistochemistry was
performed for CD31 to identify endothelial cells in combination with GFP (green, to
identify BM-derived cells), or α-SMA, NG2, or desmin (red, to identify
pericytes/vSMC). The top panels show IgG treated tumors and the bottom panels show
YW152F treated tumors. In all photos, nuclei are blue and 20x magnification was used.
protein

% reduced in
YW152F

Mann-Whitney
p-value

(positive pixels: total nuclei
ratio)

GFP
85%
0.001
87%
0.005
α-SMA
Desmin
70%
0.002
NG2
61%
0.007
Table 1. GFP, α-SMA, desmin, and NG2 were reduced in YW152F treated mice.
Five 10x fields were randomly photographed from each tumor. Simple PCI software was
used to determine the average ratio of positive pixels for the marker being evaluated (for
example, GFP) compared to nuclei present. Mean values for each marker from the
YW152F treated group were then compared to mean values for the same marker in the
IgG treatment group, and a percent reduction in YW152F group compared to IgG was
calculated (column 1). Mann-Whitney p-values for the difference in means were
calculated (column 2).
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YW152F treatment did not affect total number of CD31+ cells but did reduce the
number of open vessel lumens
To further characterize the effect of DLL4 inhibition on the tumor vascular
phenotype, we used immunohistochemistry against CD31 to identify endothelial cells.
We compared both the total CD31+ cells present in each tumor, using quantification
software, and the average number of visible vessel lumens. The average number of vessel
lumens per slide for each tumor was manually counted. There was no difference in total
CD31+ cells present in YW152F treated tumors compared to IgG control (data not
shown). There was, however, a trend towards fewer open lumens in YW152F treated
tumors compared to control (0.8 vs 2.1 lumens per 10x field, p = 0.06). The difference
between endothelial cell vascular structures in tumors of YW152F treated mice and IgG
control is visually striking. Long, lumen bearing vessels were plentiful in control tumors.
By contrast, most CD31+ structures in YW152F treated tumors were small, punctate and
non-lumen bearing (Figure 27).
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IgG
Average Lumens: 2.1

YW152F
Average Lumens: 0.8

Figure 27. The number of vessel lumens is reduced in TC71 tumors from mice
treated with YW152F compared to IgG control. Immunohistochemistry was
performed on TC71 tumor sections from mice treated with YW152F or IgG to identify
CD31+ endothelial cells. The number of open lumens in five 10x fields was manually
counted for each tumor. Average lumen number was 2.1 per 10x field in IgG treated
tumors, and 0.8 in YW152F treated tumors. p = 0.059.
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Hypoxia is increased in YW152F treated tumors
The dramatic change in tumor vessel phenotype after treatment with YW152F in
vivo, together with the lack of effect on cell proliferation in vitro on TC71 and A4573
cells implied that the observed inhibition of tumor growth might be attributable to
reduced blood vessel functionality. As a measure of vessel functionality, we examined
hypoxia within the tumors. GFP+ BM transplanted nude mice were injected
subcutaneously with TC71 cells as described previously. Beginning five days after tumor
cell injection, mice were treated twice weekly for 23 days with YW152F or IgG in the
same experimental schema used previously. Prior to sacrifice, mice were injected with
hypoxyprobe-1. Tumors were then harvested and analyzed by immunohistochemistry to
identify hypoxic regions. As shown in figure 28, the size of the hypoxic regions in
YW152F treated tumors was significantly increased compared to control (5.3 fold
increase, p = 0.003).
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Figure 28. Hypoxia is increased in YW152F treated tumors compared
to control. TC71 tumor bearing mice were treated with YW152F or IgG. Prior to
sacrifice, mice were injected with hypoxyprobe-1 (pimonidazole hydrochloride) by tail
vein injection. Tumors were then harvested and A) evaluated by immunohistochemistry
to identify hypoxic regions using anti-hypoxyprobe-1 (red). Nuclei were identified using
sytox green (green). In the merged images, hypoxic regions appear red or orange. B) The
ratio of positive pixels for hypoxia (red) to nuclei (green) was determined for five 10x
fields per tumor using Simple PCI software and averaged to obtain one value for each
tumor. Blue diamonds represent IgG treated tumors, and pink squares represent YW152F.
Black bars show mean values.
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Biotin perfusion studies were inconclusive
To compliment our demonstration of increased hypoxia and thus reduced vessel
functionality, we performed biotin perfusion studies to identify vessels with blood flow.
TC71 tumors were again implanted in nude mice that had previously received GFP BM
transplants and treated twice weekly with either YW152F or IgG control. Immediately
after sacrifice, biotin in PBS was perfused through the mouse circulation by direct
injection into the heart. Tumors were then evaluated by immunohistochemistry for biotin
and CD31. The regions of the tumor that were positive for biotin did not co-localize with
CD31, therefore they are not blood vessels. It is unclear whether this unlikely finding is
due to extensive leakage of the biotin away from vessels and into the tumor, or whether it
is due to non-specific binding of the fluorescently labeled streptavidin, which was used
during immunohistochemistry to identify biotin.
Biotin / CD31

Biotin / CD31

Figure 29. Biotin and CD31 do not co-localize in Ewing’s sarcoma. TC71 tumor
bearing mice were treated with YW152F or IgG. Immediately after sacrifice, the
circulation was perfused with biotin by direct injection into the heart.
Immunohistochemistry was performed with A) AlexaFlour 594-Streptavidin (red) to
identify biotin, and anti-CD31 (green) to identify endothelial cells, or B) AlexaFlour 488Streptavidin (green), to identify biotin and anti-CD31 (red), to identify endothelial cells.
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SUMMARY
Experiments presented in this chapter validate and expand upon our previous
findings using shDLL4 by using YW152F to inhibit DLL4 expression.
Immunohistochemical analysis demonstrated that YW152F treated tumors had
significantly reduced numbers of perivascular GFP+ BM-derived cells as well as
significantly reduced numbers of α-SMA+, desmin+, and NG2+ pericytes/vSMC. This
confirms the critical role of DLL4 in pericyte/vSMC formation in Ewing’s sarcoma.
The reduction in all three pericyte markers achieved by YW152F
treatment was more significant than that achieved by shDLL4 treatment. This is most
likely a reflection of more complete and more uniform inhibition of DLL4 by YW152F
than by intratumor injection of shDLL4. Interestingly, several of the blood vessels in
tumors treated with YW152F maintained a very thin layer of GFP+, pericyte/vSMC
marker+ cells surrounding the endothelial cells. This indicates that even when DLL4 is
inhibited, a small number of BM cells are able to adhere to the tumor vasculature, but
they do not expand into the thick layers of pericytes/vSMC observed in control tumors
during the three weeks that was allowed for tumor growth. The implications of this
observation in relation to the mechanistic function of DLL4 in vasculogenesis are
discussed in further detail in the Discussion portion of this thesis. It is also possible that
the systemic inhibition of DLL4 with YW152F caused BM cell death before the cells
reached the tumor site. However, the thin layer of BM-derived perivascular cells in
YW152F treated tumors indicates that BM cells were viable when they reached the
tumor. An in depth analysis of BM cell viability after treatment with YW152F would be
needed to definitely demonstrated that BM cells were not killed in circulation prior to
reaching the tumor. Previous experiments using shDLL4 confirmed that even when
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DLL4 is only inhibited on BM cells after they have reached the tumor, the participation
of BM-derived cells in vasculogenesis is significantly reduced.
In addition to the reduction in BM-derived pericytes/vSMC in YW152F treated
tumors, there was a change in the morphology of the endothelial cell portion of vessels.
Large, lumen bearing CD31+ vessels were apparent in IgG control treated tumors. In
contrast, CD31+ endothelial cells in YW152F treated tumors formed small, punctate
structures with few obvious lumens. This change in endothelial cell organization and
vessel structure is in agreement with previous reports of increased proliferation of
unorganized, non-functional microvessels after DLL4 inhibition 47,58.
The relationship between changed blood vessel morphology and decreased vessel
functionality was confirmed by examining hypoxia and blood vessel perfusion. Hypoxia
was increased in YW152F treated tumors compared to control, indicating reduced blood
vessel functionality.
As was expected, the reduction in blood vessel functionality negatively impacted
on tumor growth. The growth of two different Ewing’s sarcoma xenograft models, A4573
and TC71, was significantly inhibited in vivo after treatment with YW152F compared to
IgG control. This indicates that DLL4 may be a novel therapeutic target for the treatment
of Ewing’s sarcoma.
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Chapter 6.
DLL4-Notch signaling plays a role in pericyte/vSMC differentiation: In vitro
support
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RATIONALE
We have shown that DLL4 is important for BM-derived pericyte/vSMC formation
and tumor growth in Ewing’s sarcoma using both shDLL4 and YW152F. However, while
immunohistochemical analysis provides excellent evidence that when DLL4 is inhibited,
the number of BM-derived pericytes/vSMC is reduced, it provides little insight into
which part of the vasculogenesis process is controlled by DLL4-Notch signaling.
The process of BM participation in vasculogenesis is complex. BM cells must
first migrate to the tumor. We have previously shown that this process is largely mediated
by tumor cell secretion of VEGF165 32. Once BM cells reach the tumor, they must adhere
to the vasculature, proliferate, and differentiate. Little is known about which of these
processes DLL4-Notch signaling is involved in, particularly in Ewing’s sarcoma. To
determine whether DLL4-Notch signaling is critical for BM cell differentiation into
pericytes/vSMC, in vitro model systems were utilized. In this chapter, co-culture systems
with DLL4+ feeder layers and whole BM cells were established and DLL4-Notch
signaling was manipulated to determine whether the differentiation pathway of BM cells
would be altered. Additionally, 10T1/2 mesenchymal cells were used to examine the
effects of active Notch signaling on pericyte/vSMC marker expression during the
pericyte/vSMC maturation process.
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RESULTS
BM cell expression of pericyte markers in vitro is partially DLL4 dependent
We first determined whether DLL4 signaling is necessary for immature BM cells
to begin expressing markers of differentiated pericytes/vSMC. SC9-19 embryonic mouse
stromal cells, which express DLL4, were used as a feeder layer. Whole BM was collected
from the femurs of GFP transgenic mice (thus BM cells were GFP+) and plated on top of
a monolayer of SC9-19 cells. Co-cultured cells were treated with either IgG control or
YW152F for one week (5μg/ml, refreshed daily). BM cells were then collected by FACS
for GFP+ cells, and RNA was analyzed by RT-PCR. The pericyte/vSMC markers RGS5
and desmin were reduced (46% and 40%, respectively) in YW152F treated BM cells
compared to IgG control (Figure 30a).
We next wished to determine whether DAPT, a γ-secretase inhibitor, which
inhibits all Notch receptor signaling, would have an even more profound effect on BM
cell differentiation into pericyte-like cells. The co-culture experiment described above
was repeated, but this time co-cultured cells were treated daily with either γ-secretase
inhibitor (100μM) or YW152F (2.8μg/mL). As expected, treatment with γ secretase
inhibitor further reduced the expression of desmin and RGS5 compared to YW152F
treated or untreated cells (Figure 30b). RT-PCR for the downstream Notch effector Hey2
showed that while YW152F treatment only partially reduced Hey2 expression (53%), γsecretase inhibition more completely inhibited Hey2 mRNA expression (97%), implying
more complete blockage of the Notch pathway.
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Figure 30. Inhibition of DLL4 or Notch reduces the expression of pericyte markers
RGS5 and desmin by BM cells in co-culture. Whole BM was collected from GFP
transgenic mice femurs and co-cultured with SC9-19 cells for one week. A) Co-cultured
cells were treated daily with YW152F or IgG. GFP+ BM cells were collected by FACS
and RT-PCR was performed for RGS5 and desmin. Densitometry quantification was
performed. B) Co-cultured cells were treated daily with DAPT or YW152F. GFP+ BM
cells were collected by FACS and RT-PCR was performed for desmin, RGS5, and Hey2.
Densitometry quantification was performed. Experiments were performed three times
with similar results; data shown is representative.

Notch regulates expression of pericyte/vSMC markers in 10T1/2 cells
After demonstrating that inhibition of either DLL4 or Notch impairs BM cell
expression of pericyte/vSMC markers, we wished to determine whether active Notch
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signaling can induce upregulation of pericyte/vSMC markers. 10T1/2 cells, pluripotent
mesenchymal cells that can differentiate into pericyte-like cells in culture, were utilized
68

.
MigR1-GFP plasmids containing DNMAM (to inhibit Notch signaling), the

intracellular domain of Notch 1 (NICD1, to mimic active Notch 1), and Hes1 (a
downstream mediator of Notch signaling), were transfected into 10T1/2 cells. Forty eight
hours after transfection, RNA was collected and RT-PCR was performed. DNMAM
reduced RGS5 mRNA compared to 10T1/2 control (Figure 31a, column 2). Conversely,
NICD1 increased expression of all three pericyte/vSMC markers measured: desmin,
RGS5, and PDGFR-β (Figure 31a, column 3). Transfection with MigR1-GFP/Hes1
increased expression of desmin, but not RGS5 or PDGFRβ (Figure 31a, column4). The
lack of induction of RGS5 or PDGFRβ by Hes1 indicates that another mediator of the
Notch pathway, possibly another member of the Hes or Hey family, is responsible for the
induction of RGS5 and PDGFRβ mRNA expression. We therefore examined Hes1,
Hey1, and Hey2 expression in 10T1/2 cells transfected with MigR1 control, DNMAM,
NICD1, DLL4, or Hes1 to determine whether these Notch effectors may be candidates
for the regulation of RGS5 and PDGFR-β. Hes1 was constitutively expressed in 10T1/2
cells, even in the presence of DNMAM, and was not increased by NICD1 or DLL4
(Figure 31b). This indicates that Hes1 expression in 10T1/2 cells is regulated by a
pathway other than Notch. Hey1 mRNA, and to a lesser extent Hey2 mRNA, was
increased in 10T1/2 cells transfected with either NICD1 or DLL4 compared to nontransfected or control transfected cells. Hey1 and Hey2 may be intermediates in the
regulation of RGS5 and PDGFRβ by Notch.
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To determine whether the induction of pericyte/vSMC marker expression is
unique to Notch 1 or can be achieved by the other Notch receptors, MigR1-GFP plasmids
containing the intracellular domains of each of the four mammalian Notch receptors
(NICD1-4) were transfected into 10T1/2 cells. Forty eight hours after transfection, RNA
was collected, RT-PCR and real time PCR was performed. Transfection with each of the
four NICDs led to increased RGS5 and desmin expression compared to control MigR1GFP (Figure 31c). This indicates that active Notch signaling, by either direct or indirect
mechanisms, stimulates the expression of pericyte/vSMC markers during the progression
from an immature progenitor cell towards a mature pericyte/vSMC.
In addition to the reduction of RGS5 expression described above, MigR1GFP/DNMAM transfected 10T1/2 cells underwent a dramatic change in phenotype
compared to MigR1-GFP control transfected cells. Control cells maintained the parental
culture phenotype of elongated, spindle shaped cells while MigR1-GFP/DNMAM
transfected cells become rounded and formed clumps on the culture dish (Figure 32).
Together with the reduction in expression of RGS5, this rounded morphology indicates a
less differentiated state following Notch inhibition.
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Figure 31. Notch induces pericyte/vSMC marker expression in 10T1/2 cells. 10T1/2
cells were transfected with various MigR1 plasmids. Forty eight hours later, RNA was
collected and RT-PCR or real time PCR was performed. A) RT-PCR for desmin, RGS5,
and PDGFRβ was performed on RNA from 10T1/2 cells transfected with MigR1GFP/DNMAM, NICD1, or Hes1. B) RT-PCR for Hes1, Hey1, and Hey2 was performed
on RNA from 10T1/2 cells transfected with MigR1-GFP control, MigR1-GFP/DNMAM,
NICD1, DLL4, or Hes1. C) Real time PCR for RGS and desmin was performed on RNA
from 10T1/2 cells transfected with MigR1-GFP control, MigR1-GFP/NICD1,2,3, or 4.
Relative mRNA levels compared to MigR1-GFP control was calculated. Experiments
were repeated at least twice with similar results.
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Figure 32. DNMAM changes the morphology of 10T1/2 cells in culture. 10T1/2 cells
were transfected with MigR1-GFP or MigR1-GFP/DNMAM. Forty-eight hours later,
brightfield and fluorescent microscopy was performed. 10x maginification.
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SUMMARY
Co-culture experiments presented here confirm that a portion of whole BM cells
cultured on a DLL4+ feeder layer will begin to express the pericyte/vSMC markers RGS5
and desmin, indicating a progression towards pericyte/vSMC maturation. Further, this coculture system was used to demonstrate that inhibition of DLL4 by YW152F leads to a
reduction in expression of RGS5 and desmin by BM cells. This demonstrates that DLL4
is important for the maturation and/or differentiation process as BM-derived cells become
pericytes/vSMC.
A second series of co-culture experiments using γ secretase inhibitors and
YW152F, demonstrated that DAPT, a γ secretase inhibitor, more effectively reduces the
expression of RGS5 and desmin than YW152F. The Notch effector Hey2, which is
directly induced by activated Notch receptors, was also more significantly reduced by
treatment with the γ secretase inhibitor. One possible explanation for this is that at the
doses used the γ secretase inhibitor is more efficient than YW152F, and equal reduction
in Notch effector expression as well as equal reduction in RGS5 and desmin might be
achieved with increased concentrations of YW152F. A more likely explanation is that in
addition to DLL4, other Notch ligands are also involved in the differentiation of BM cells
into pericytes/vSMC, and inhibition of DLL4 only inhibits a portion of the Notch
signaling needed for the process. This possibility is supported by studies by Doi et al.,
demonstrating that the Notch ligand Jagged 1 plays an important role in vSMC formation
69

.
Experiments performed using 10T1/2 mesenchymal precursor cells further

support the finding that DLL4-Notch signaling plays a role in the regulation of
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expression of pericyte markers. The active domain of each Notch receptor as well as the
Notch inhibitor DNMAM was transfected into 10T1/2 cells. Each NICD increased RGS5
and desmin mRNA, indicating progression towards pericytes/vSMC. Conversely, when
Notch was inhibited in 10T1/2 cells by DNMAM, RGS5 mRNA was reduced, and the
cells changed from an elongated, spindle shaped morphology to a rounded, clumped
morphology. Together, the reduction in RGS5 with the rounded morphology is indicative
of a reversion to a less differentiated state when Notch signal is inhibited.
Taken together, our findings using a co-culture system and 10T1/2 cells
demonstrate a role for Notch signaling in the regulation of expression of the pericyte
markers RGS5 and desmin at the mRNA level. This indicates that Notch signaling is
involved in the maturation of pericyte progenitor cells into pericytes/vSMC, and supports
our in vivo finding of reduced numbers of pericytes/vSMC when DLL4 is inhibited.
In the canonical Notch signaling pathway, NICD translocates to the nucleus
where it becomes part of a transcriptional activating complex. The complex then induces
expression of Notch effector proteins, such as Hes and Hey family members, which are
themselves transcription factors. These Notch effectors then regulate the expression of
downstream Notch targets. We demonstrated that when 10T1/2 cells are transfected with
MigR1-GFP/Hes1, the Notch effector Hes1 induces increased mRNA levels of desmin
but not RGS5 or PDGFR-β, indicating that other Notch effectors may also be involved in
transducing the Notch signal to induce expression of pericyte/vSMC markers. We
demonstrated upregulation of Hey1 and Hey2 by NICD1 and DLL4 in 10T1/2 cells. This
indicates that these Notch effectors may be involved in pericyte/vSMC differentiation
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and/or maturation. Further study of the individual roles of Hey1, Hey2 and other Notch
effectors during pericyte/vSMC maturation is warranted.
Interestingly, the above experiments were performed in vitro without Ewing’s
sarcoma cells present. This demonstrates that Notch partially regulates BM cell
maturation into pericyte/vSMC maturation even outside of the Ewing’s sarcoma
environment. These studies may therefore have more broad implications regarding the
role of Notch signaling in pericyte/vSMC formation and differentiation in other tumors or
in vasculogenesis in normal tissue.
It is important to note that DLL4-Notch signaling may be involved in more than
one step of BM cell participation in vasculogenesis. While the findings presented here
support a role for Notch signaling in BM cell to pericyte/vSMC differentiation and/or
maturation, they do not support nor refute a role for DLL4-Notch signaling in BMderived cell adhesion to vessels or in pericyte/vSMC proliferation.
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Chapter 7.
Discussion
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Figure 33. Proposed model of DLL4-Notch signaling during BM cell maturation into
pericytes/vSMC. A) Schematic diagram of BM cell participation in vasculogenesis.
Immature BM cells (green) migrate to the tumor and adhere to sites of developing blood
vessels. After a BM cell has reached the vessel wall, DLL4 on one BM cell activates
Notch receptors on neighboring BM cells, signaling the immature BM cells to activate
pericyte/vSMC maturation pathways and differentiate into pericytes/vSMC (pink cells).
B) Intracellular signaling. When DLL4 binds to Notch receptor on a neighboring BM
cell, the receptor is cleaved and NICD (purple lightning bolt) translocates to the nucleus
where it forms a transcriptional activating complex including MAML, RBP-Jk, and
CBP/300. The complex induces transcription of Notch effectors of the Hes and Hey
family, which are themselves transcription factors. The Notch effectors then either
directly or indirectly induce expression of pericyte/vSMC markers α-SMA, desmin,
RGS5, NG2 and PDGFRβ during the pericyte maturation process.
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We have previously used various mouse BM transplant models to demonstrate
that BM-derived cells contribute to vascular development in Ewing’s sarcoma by
differentiating into both endothelial cells and pericytes/vSMC 63,70-72. We further
demonstrated that vasculogenesis is essential for the growth of Ewing’s sarcoma in vivo.
This was done by selectively inhibiting vasculogenesis but not angiogenesis, which
resulted in small, avascular tumors 62. The first step in vasculogenesis, migration of BM
cells to the tumor, is largely mediated by the chemoattractant properties of VEGF165 70,71.
The molecular signals that contribute to the regulation of BM cell differentiation into
pericytes/vSMC are poorly understood. Here, we demonstrated for the first time a critical
role for DLL4-Notch signaling in BM cell differentiation into pericytes/vSMC during
vasculogenesis in Ewing’s sarcoma. The inhibitory role of DLL4-Notch signaling in
endothelial cell proliferation and vessel sprouting during angiogenesis is well established.
However, we are the first to demonstrate a role for DLL4 in regulating BM-derived
pericyte/vSMC formation during vasculogenesis. We are also the first to demonstrate that
inhibiting DLL4 inhibits the growth of Ewing’s sarcoma in vivo, indicating that DLL4
may be a therapeutic target for the treatment of patients with Ewing’s sarcoma.
DLL4 expression by BM-derived pericytes/vSMC in Ewing’s sarcoma
Previously, DLL4 expression by endothelial cells in blood vessels of developing
tissues as well as in several tumor models has been reported. While DLL4 expression
during physiologic blood vessel development, for example in the developing retina, is
restricted only to endothelial tip cells at the growing vessel front, endothelial cells along
the length of the vessel express DLL4 in several tumors, for example, in S180 sarcomas
in mice 59,73. We therefore expected to find DLL4 expression by endothelial cells in
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Ewing’s sarcoma. Surprisingly, in addition to a few DLL4+ CD31+ endothelial cells,
DLL4 was expressed by BM-derived pericytes/vSMC in Ewing’s sarcoma vasculature.
Several thick layers of DLL4+ cells were observed in two xenograft models of Ewing’s
sarcoma, TC71 and A4573. We are the first to report expression of DLL4 by perivascular
cells in tumor vasculature. We therefore confirmed the DLL4 expression pattern using a
second anti-DLL4 antibody.
The relevance of this finding to the human disease was confirmed by
immunohistochemistry on human Ewing’s sarcoma tumor specimens, where 12 of 14
patient samples had similar DLL4+ perivascular layers. The perivascular location and the
histology of the cells on the adjacent hematoxylin and eosin stained sections suggests that
the DLL4+ cells are pericytes/vSMC. However, we could not perform dual staining on
the patient samples to confirm that DLL4+ cells are pericytes/vSMC due to limitations of
immunohistochemical staining on paraffin embedded sections.
We have previously demonstrated that the majority of blood vessels in Ewing’s
sarcoma are surrounded by thick layers of BM-derived pericytes/vSMC that express
PDGFRβ, α-SMA, and desmin 63. Here, we demonstrated that DLL4 co-localizes with
the pericyte/vSMC markers desmin and α-SMA, suggesting that the DLL4+ cells are
pericytes/vSMC. In the DLL4 and desmin double-stained tumor sections, the vast
majority of DLL4+ cells were also desmin+. However, there were several desmin+DLL4cells present, suggesting that not all desmin+ pericytes/vSMC express DLL4. DLL4 and
α-SMA co-localized to a lesser extent than DLL4 and desmin. Several DLL4+α-SMAcells were present, and vice versa, several α-SMA+DLL4- cells were also present. This
suggests that some α-SMA+ pericytes/vSMC do not express DLL4 and some DLL4+ cells
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do not express α-SMA. Taken together, the finding of desmin+ and α-SMA+ cells that do
not express DLL4 suggests that there is a pericyte/vSMC population present in Ewing’s
sarcoma tumors that are DLL4-.
The pericytes/vSMC in Ewing’s sarcoma are a mosaic of locally derived and BMderived cells 33. We used a GFP BM transplant model to demonstrate that DLL4
expression extensively co-localizes with GFP+ BM-derived cells in Ewing’s sarcoma
(greater than 90% co-localization). One possible explanation for the near complete colocalization of DLL4 with GFP but only partial co-localization of DLL4 with
pericyte/vSMC markers is that DLL4 is expressed by BM-derived pericytes/vSMC but
not locally derived pericytes/vSMC. To confirm this, flow cytometry could be performed
on homogenized tumors from GFP BM transplanted mice to determine the percentage of
GFP- (non-BM-derived) but desmin+ or α-SMA+ (pericyte/vSMC) and DLL4+ cells
present. If non-BM derived pericytes/vSMC do not express DLL4, then we would expect
to see few or no pericyte/vSMC that are DLL4+ but GFP-.
Though novel and therefore surprising, our demonstration of DLL4 expression by
BM-derived pericytes/vSMC has recently been supported by evidence of DLL4
expression by other non-endothelial cell types. For example, DLL4 is expressed by
neoplastic goblet cells in colon cancer, normal endometrial epithelial and stromal cells,
thymic epithelium, and regulatory T cells 74-76.
The extensive number of GFP+ BM-derived cells surrounding CD31+ endothelial
cells is somewhat unique to Ewing’s sarcoma, and suggests that in addition to
pericytes/vSMC, BM-derived cells may be contributing to other cell populations within
the tumor. While a small portion of the GFP+ BM-derived cells in Ewing’s sarcoma are
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macrophages and monocytes (F4/80+ or CD14+), the majority are not. The GFP+
macrophages and monocytes are spread throughout the tumor and do not make up the
bulk of perivascular BM-derived cells 30.
Another possibility is that a portion of the perivascular GFP+ cells are fibroblasts.
Fibroblasts can be BM-derived, can be in perivascular locations, and can express several
of the same markers as pericytes/vSMC 77. Immunohistochemistry for the fibroblast
marker S100A4 demonstrated that fibroblasts are present in Ewing’s sarcoma tumors.
However, the fibroblasts are spread throughout the tumor mass. The majority of CD31+
blood vessels had no or very few perivascular fibroblasts surrounding them. Co-staining
for GFP, to identify BM-derived cells, and S100A4, to identify fibroblasts, demonstrated
that the majority of BM-derived cells within TC71 tumors are not fibroblasts.
The role of Notch in BM cell participation in vasculogenesis
After demonstrating DLL4 expression by BM-derived pericytes/vSMC, we
sought to determine what role DLL4-Notch signaling might play in BM cell participation
in vasculogenesis. While BM-derived pericytes/vSMC have been observed in several
different physiologic and pathologic settings, such as in the retinal and femoral arteries
after injury and in the vasculature of glioblastomas, little is known about the molecular
signals that direct the formation of BM-derived pericytes/vSMC postnatally 42,78,79. The
expression of DLL4 by BM-derived pericytes/vSMC in Ewing’s sarcoma suggests that
DLL4-Notch signaling might be involved in this process.
Inhibition of DLL4 causes hyperproliferation of unorganized, non-functional
microvessels. These vessels are immature as determined by their lack of pericyte/vSMC
coverage and lack of blood perfusion. A correlation between DLL4 expression and α-
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SMA+ cell coverage in bladder cancer and lymphomas has been demonstrated 47,60. There
are several possible explanations for why the loss of the DLL4 signal leads to the
proliferation of immature vessels that lack pericyte coverage. One possibility is that the
endothelial cells are proliferating so rapidly that pericytes/vSMC can not keep up. In this
case, endothelial cells can be imagined in two states: An immature state, where
proliferation and sprouting are active and therefore pericyte recruitment signals are
downregulated by endothelial cells, and a mature state, where endothelial cell
proliferation is stopped and pericytes/vSMC are recruited. In this model, the role of
DLL4-Notch signaling is simply to induce a mature, quiescent state of endothelial cells,
allowing for pericyte coverage. This model is supported by the role of DLL4-Notch1 in
tip vs. stalk cell identity. DLL4 stimulation of Notch1 is necessary for endothelial cells to
assume the stalk cell phenotype. When either DLL4 or Notch1 is inhibited, endothelial
cells proliferate excessively in vitro and extend filopodia (indicating tip cell phenotype)
in vivo 52,53. This indicates that the loss of DLL4 causes endothelial cells to enter into a
proliferative state where pericytes/vSMC are not recruited to the vessel.
Another possibility is that in addition to the need for endothelial cells to be in a
quiescent, mature state, Notch signaling directly informs immature pericyte precursor
cells to adhere to sites of developing vasculature, proliferate, and/or differentiate into
pericytes/vSMC. This model is supported by the phenotype of Notch3 knockout mice.
The arteries in these mice are enlarged and have reduced pericyte/vSMC coverage, but do
not display increased branching or sprouting 45. This indicates defective pericyte/vSMC
formation without hyperproliferation of endothelial cells. Regulation of pericyte/vSMC
coverage independent of endothelial cell proliferation is suggested by this phenotype. It is
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important to note that these two possible models are not mutually exclusive; a reduction
in pericyte/vSMC coverage of vessels in the absence of DLL4 could be due in part to a
prolonged immature, hyperproliferative state of endothelial cells and in part to a direct
role for Notch signaling in BM cell differentiation into pericytes/vSMC. Little is
understood about which of these two models, if either, DLL4-Notch signaling regulates.
After determining that DLL4 is expressed by BM-derived pericytes/vSMC in
Ewing’s sarcoma, and with both of the above mentioned models in mind, we
hypothesized that the DLL4 expressed by BM cells activates Notch receptors on
surrounding BM cells during the process of maturation from immature BM cell to
pericyte/vSMC. This hypothesis assumes that DLL4-Notch signaling is involved in
pericyte/vSMC differentiation or maturation independently of the endothelial cell
proliferative state. In support of this hypothesis, immunohistochemical evaluation of
TC71 tumors from mice that had received GFP BM transplants revealed similar patterns
of GFP, DLL4, and NICD1 on adjacent tumor sections. Additionally, GFP+ BM-derived
cells isolated from TC71 tumors expressed DLL4 and the Notch effector Hes1, Hey1, and
Hey2 mRNA, as demonstrated by RT-PCR and real time PCR. Expression of these Notch
effectors indicates active Notch signaling. Together, these data indicate that Notch
receptors are active in BM-derived cells within Ewing’s sarcoma tumors.
MigR1-GFP/DNMAM was used to inhibit Notch signaling in BM cells, and BM
transplants were performed. Tumors from mice with MigR1-GFP/DNMAM BM had
dramatically reduced perivascular BM cells compared to control. This indicates that
without the ability to receive Notch signals, BM cell adherence to developing vessels
and/or differentiation into pericytes/vSMC is severely inhibited. Another possibility is
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that the expression of DNMAM in BM cells was toxic and reduced the number of viable
BM-derived pericyte precursor cells prior to the cells reaching the tumor. Mice received
MigR1-GFP/DNMAM BM transplants one month prior to injection of tumor cells, and
no toxicity was observed. Mice remained healthy and active throughout the duration of
the experiment. If extensive BM cell toxicity had occurred due to expression of
DNMAM, we would expect to have seen some indication in the health of the mice.
However, to definitely disprove the possibility of BM cell death prior to reaching the
tumor due to DNMAM, extensive evaluation of the whole mouse BM would need to be
performed at the end of the experiment.
Recently, Doi et al. reported high expression of Notch3 and Jagged1 by BMderived α-SMA+ vSMC in the neointima of the femoral artery after wire injury in mice 42.
However, they did not examine whether this high expression of Notch3 plays a functional
role in vSMC formation. Our demonstration of reduced numbers of perivascular BMderived cells in tumors from mice that had received DNMAM BM transplants suggests
that the expression of Notch receptors and the ability of BM cells to receive the Notch
signal is functionally important for BM-derived pericyte/vSMC formation.
A role for DLL4 in BM-derived pericyte/vSMC formation in vivo
DLL4 inhibition in several tumor models, including breast, colon, and lung
cancer, correlated with a decrease in α-SMA+ cell coverage and decreased vessel
functionality, ultimately inhibiting tumor growth. However, this decreased vessel
functionality has previously been attributed to excessive angiogenic sprouting of
endothelial cells. The role of DLL4 in vasculogenesis specifically has not been studied.
Due to the high number of BM-derived pericytes/vSMC and the essential role of
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vasculogenesis in Ewing’s sarcoma tumor growth, Ewing’s sarcoma is a unique model
for the study of the role of DLL4 in blood vessel formation by the process of
vasculogenesis. Studies of the role of DLL4 in vascular formation and tumor growth in
Ewing’s sarcoma have not been previously reported.
We used two different methods to inhibit DLL4 signaling, shDLL4 and YW152F,
to confirm and expand upon findings in other tumor models. While a reduction in αSMA+ cells after DLL4 inhibition has been reported, evaluation of other pericyte/vSMC
markers after DLL4 inhibition has not been previously evaluated. To our knowledge, we
are the first to extensively evaluate the effects of DLL4 inhibition on BM-derived cell
participation in vascular development and pericytes/vSMC formation using multiple
pericyte/vSMC markers. Inhibition of DLL4 using either shDLL4 or YW152F
significantly decreased the number of BM-derived pericytes/vSMC in Ewing’s sarcoma
tumors. This was demonstrated by immunohistochemical evaluation of GFP (to identify
BM-derived cells), desmin, NG2, and α-SMA (to identify pericytes/vSMC). GFP+ BMderived cells and expression of all three pericyte/vSMC markers were significantly
decreased in YW152F treated tumors. In shDLL4 treated tumors, GFP expression was
not quantified although the reduction was visually apparent. Desmin and α-SMA were
significantly decreased, and the reduction in NG2 bordered significance. The greater
reduction in BM-derived pericytes/vSMC by treatment with YW152F compared to
shDLL4 is probably due to the more complete suppression of DLL4 signaling afforded
by systemic delivery of YW152F. In the shDLL4 model, DLL4 expression was not
equally downregulated throughout treated tumors; regions of each tumor still had some
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DLL4+ cells. In the vessels where DLL4 remained, so did the BM-derived
pericytes/vSMC.
In addition to a reduction in BM-derived pericyte/vSMC coverage, the CD31+
vessel morphology was altered in tumors of YW152F treated mice. Blood vessels in
control tumors were elongated, well-organized, and often had visible lumens. CD31+
structures in YW152F treated tumors, however, were often small, punctate, and nonlumen bearing. This observation is in agreement with prior observations by several labs,
including Scehnet et al., who demonstrated that treatment of HT29 colon carcinoma
xenografts with soluble DLL4 (dominant negative DLL4) leads to “decreased or absent
vascular lumen”59. We further demonstrated that the change in vascular morphology
correlates with a decrease in blood vessel functionality. Hypoxia was significantly
increased in shDLL4 and YW152F treated tumors compared to controls. Presumably,
increased hypoxia is due to reduced delivery of oxygenated blood to tumor cells and is
representative of decreased vessel functionality.
Most importantly, the change in vessel morphology and reduced vessel
functionality due to inhibition of DLL4 by YW152F correlated with a significant
inhibition of tumor growth in both TC71 and A4573 xenograft models. This inhibition
was not due to a direct effect of the antibody on tumor cell viability or proliferation;
YW152F did not affect TC71 or A4573 viability or proliferation in vitro. Taken together,
these studies indicate that the inhibition of DLL4 leads to a reduction in the number of
BM-derived pericytes/vSMC and fewer large lumen-bearing vessels, which impairs blood
vessel functionality and ultimately inhibits tumor growth in Ewing’s sarcoma.

95

We have previously demonstrated that inhibition of vasculogenesis in Ewing’s
sarcoma inhibits tumor growth 62. However, this was done by genetic manipulation of
BM cells to prevent their migration to the tumor and therefore did not represent a
therapeutically relevant method of inhibiting vasculogenesis. Our demonstration of tumor
growth inhibition by treatment with YW152F indicates that DLL4 could be a therapeutic
target for the treatment of patients with Ewing’s sarcoma.
DLL4-Notch: Role in BM cell differentiation into pericytes/vSMC during
vasculogenesis
Our in vivo data does not clearly distinguish which step of the vasculogenesis
process DLL4-Notch signaling is important for: BM cell adhesion to the endothelial cells
of developing vasculature, migration to the extra-luminal side of vessels, proliferation, or
differentiation into pericytes/vSMC. Caiado et al. recently demonstrated a role for Notch
in BM cell adhesion at sites of developing vasculature. Lin-Sca1+ BM cells treated with γsecretase inhibitor displayed a reduced ability to bind to extracellular matrix components
in vitro, and a decreased capacity to participate in wound healing in vivo80.
Interestingly, in our work, many of the vessels in YW152F treated tumors had a
very thin layer of GFP+ BM-derived pericytes/vSMC. This seems to indicate that
incoming BM-cells are able to adhere to the vessel wall, extravasate and even begin
expressing pericyte/vSMC markers, but at a significantly reduced rate compared to
control tumors. One explanation for this is that even when DLL4 is inhibited by YW152F
other Notch ligands, possibly DLL1, expressed by endothelial cells, or Jagged1,
expressed by endothelial and vSMC, are able to partially compensate for the loss of
DLL4. In that case, our data can be reconciled with Caiado’s demonstration of reduced
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BM cell adhesion by treatment with a γ-secretase inhibitor because the reduced adhesion
may be due to inhibition of signaling by another Notch ligand 49,80,81.
In support of a role for DLL4 in the stimulation of immature BM-derived cells to
begin differentiating toward a pericyte/vSMC fate, YW152F dramatically reduced
expression of RGS5 and desmin mRNA by BM cells in co-culture in vitro. Treatment
with DAPT, a γ-secretase inhibitor and pan Notch inhibitor, more completely reduced
mRNA levels of RGS5 and desmin. Further, the Notch effector Hey2 mRNA was
reduced roughly 50% by YW152F but greater than 95% by DAPT. Hey2 is a downstream
target of active Notch signaling and is a surrogate marker for Notch pathway activation.
The remaining Hey2 after YW152F treatment indicates that another Notch ligand is
stimulating Notch receptors in the absence of DLL4 stimulation, and this stimulation is
inhibited further by pan Notch inhibition with a γ-secretase inhibitor.
Inhibiting DLL4 or Notch receptor activation in BM cells in co-culture reduced
pericyte/vSMC marker expression. To compare the effects of Notch inhibition to
stimulation of the Notch pathway, we introduced DNMAM, NICD1, or Hes1 into 10T1/2
mesenchymal precursor cells. While DNMAM reduced RGS5 mRNA, NICD1 increased
desmin, RGS5, and PDGFR-β mRNA expression. This demonstrates a stimulatory effect
of Notch signaling for pericyte/vSMC differentiation. Our data is supported by evidence
from Jin et al demonstrating that both NICD1 and NICD3 induce PDGFR-β upregulation
by vSMC in vitro 82.
Interestingly, while NICD1 increased RGS5, desmin and PDGFR-β in 10T1/2
cells, Hes1 only increased desmin mRNA. This implies that either Notch directly induces
desmin and PDGFR-β expression (by binding directly to the gene’s promoter and
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bypassing Notch effectors), or other Notch effectors are involved. Jin et al demonstrated
binding of NICD1 to the PDGFR-β promoter, indicating direct regulation of PDGFR-β
by Notch1 82. However, the mechanism by which Notch stimulates RGS5 and desmin
upregulation is unknown. We demonstrated increased Hey1 and Hey2 expression in
10T1/2 cells following transfection with NICD1 and DLL4 plasmids. Hey1 or Hey2 may
therefore be intermediate mediators of Notch regulation of RGS5 and desmin expression.
We are the first to demonstrate increased RGS5 and desmin expression by NICD1
and to confirm NICD1 upregulation of PDGFR-β in 10T1/2 cells. Previously, Notch3
stimulation of pericyte/vSMC maturation has been indicated by the demonstration that
Notch3 upregulates α-SMA expression 83. However, to our knowledge, an examination
of the activity of all four Notch receptors during pericyte/vSMC differentiation and/or
maturation in the same model system has not been reported. Transfection of 10T1/2 cells
with each of the four active Notch receptors, NICD1-4, increased expression of RGS5
and desmin. It is important to note that the relative potency of one receptor compared to
another cannot be evaluated in this assay because the transfection efficiency of each
MigR1-GFP/NICD plasmid into the 10T1/2 cells was not equal. This assay is therefore
qualitative, and demonstrates that each of the four Notch receptors has the capacity to
induce increased mRNA expression of RGS5 and desmin in 10T1/2 cells.

98

Conclusion
DLL4-Notch signaling is critical for the formation of BM-derived
pericytes/vSMC. Due to this critical role of DLL4, DLL4 is essential to the process of
vasculogenesis and the formation of functional vasculature in Ewing’s sarcoma, and is
thus essential for Ewing’s sarcoma tumor growth.
We have demonstrated:
1. DLL4 is expressed by BM-derived pericytes/vSMC in Ewing’s sarcoma.
This was demonstrated in 12 out of 14 patient samples and in TC71 and A4573
xenograft models.
2. DLL4 is critical for the formation of BM-derived pericytes/vSMC in Ewing’s
sarcoma.
This was demonstrated by inhibition of DLL4 using shDLL4 and YW152F in
both T7C1 and A4573 models. Pericytes/vSMC were identified by using
immunohistochemistry for α-SMA, NG2, and desmin.
3. DLL4 is a valid therapeutic target for the treatment of Ewing’s sarcoma.
This was demonstrated by treating TC71 or A4573 tumor bearing mice with
YW152F or IgG control. YW152F significantly inhibited the growth of both
tumor models.
4. Notch signaling regulates the expression of the pericyte/vSMC markers RGS5,
desmin, and PDGFR-β in vitro.
This was demonstrated by co-culturing whole BM cells with SC9-19 cells in the
presence of YW152F or IgG. It was further demonstrated by transfecting the
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Notch intracellular domains into 10T1/2 cells and measuring the expression of
pericyte/vSMC markers.
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FUTURE DIRECTIONS
Determining how Notch regulates pericyte/vSMC marker expression
We have demonstrated that the Notch effectors Hes1, Hey1, and Hey2 are present
in GFP+ BM cells isolated from TC71 tumors. We also demonstrated that each of the
NICDs can induce expression of the pericyte/vSMC markers RGS5 and desmin in 10T1/2
mesenchymal precursor cells. However, the mechanism by which NICD induces this
increase in pericyte/vSMC marker expression is largely unknown. In the canonical Notch
signaling pathway, Notch receptor activation can lead to expression of multiple Notch
effectors, including Hes and Hey family members, which may then directly or indirectly
regulate RGS5 and desmin expression. A role for Hes1 and HeyL, for example, is
suggested by work Liu et al, demonstrating that co-culture of endothelial cells and human
smooth muscle cells led to increased expression of Hes1 and HeyL in smooth muscle
cells 83. The authors did not determine the functional effect of Hes1 or HeyL
upregulation. To determine whether a Hes or Hey transcription factor is involved in
Notch regulation of desmin and RGS5 expression, transfection of 10T1/2 cells with
MigR1/Hes or MigR1/Hey constructs could be used. Individual MigR1/Hes (Hes 1,2,4,5)
or MigR1/Hey(1,2,L) would be transfected into 10T1/2 cells. Forty-eight hours later,
RNA would be collected and analyzed by RT-PCR for changes in expression levels of
RGS5, PDFR-β and desmin. If the amount of RGS5, PDGFR-β or desmin increases after
transfection with one of the Notch effectors, that indicates a potential role for that
effector as a specific intermediate in the stimulation of pericyte/vSMC maturation by
Notch. If there is no change in the expression of pericyte/vSMC markers after
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transfection with a particular Hes or Hey, then that Hes or Hey is probably not an
intermediate in the pericyte/vSMC regulatory pathway by Notch.
Other non-canonical mechanisms may also mediate Notch regulation of
pericyte/vSMC differentiation. For example, NICD can directly bind to gene promoters
to induce transcription. In human aortic smooth muscle cells, the NICD1-RBP-Jk
complex can directly bind to the α-SMA promoter and induce gene expression in vivo,
and in vSMC, NICD1 can bind to the PDGFR-β promoter 82,84. To determine whether a
NICD is able to directly bind to the promoter of RGS5 or desmin, ChIP assays could be
employed using antibodies for each of the individual Notch intracellular domains and
primers specific for the promoter regions of RGS5 or desmin. 10T1/2 cells could be
transfected with either MigR1 control or MigR1/NICD1,2,3, or 4. Forty eight hours later,
ChIP assay would be performed to determine whether any of the NICDs are bound to the
promoters of RGS5 or desmin. If an NICD is bound to the promoter of either RGS5 or
desmin, that indicates that regulation of the gene by Notch signaling may be directly
through the Notch receptor without intermediate Notch effectors.
Translational Applications of DLL4 inhibition
We have demonstrated that DLL4 inhibition by either shDLL4 or the monoclonal
antibody YW152F significantly inhibits Ewing’s sarcoma growth in vivo. This suggests
that DLL4 may be a valid therapeutic target for the treatment of Ewing’s sarcoma. A
monoclonal anti-DLL4 antibody, REGN421, has been developed by Regeneron
Pharmaceuticals. A multiple-ascending-dose phase I trial to determine the safety and
tolerability of REGN421 is currently underway. Adult patients with advanced solid
malignancies are included in the patient population that can participate in the study, with
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specific eligibility criteria. Plans for a pediatric trial of REGN421 at St. Jude Children’s
Hospital (Memphis, TN) are currently being developed. The phase I testing of REGN421
in conjunction with our demonstration of the efficacy of the DLL4 neutralizing antibody
YW152F against Ewing’s sarcoma is exciting. However, there are several factors to be
considered and further experimentation is needed to determine whether anti-DLL4
therapy is appropriate for the treatment of pediatric patients with Ewing’s sarcoma.
Post-YW152F effects
In both the shDLL4 and YW152F treatment schemas presented in this
dissertation, treatment was begun five days after tumor inoculation and mice were
sacrificed within three days of the final treatment. We have demonstrated that during a
three or four week period where shDLL4 or YW152F is administered regularly, tumor
growth is significantly inhibited. However, particularly when a therapy is to be used in a
pediatric population, the long term effects after cessation of therapy must be understood.
It is therefore important to understand both immediate effects after cessation of therapy
and what, if any, permanent toxicity is associated with anti-DLL4 therapy.
The most pertinent concern about immediate effects after cessation of anti-DLL4
therapy is the possibility of a rebound in tumor growth. To determine whether Ewing’s
sarcomas are likely to rebound rapidly after cessation of anti-DLL4 therapy, an
experimental schema similar to the one used in chapter five could be utilized. Tumor
bearing mice would be treated twice weekly with i.v. YW152F or IgG for several weeks.
After the final treatment, mice would be allowed to live until the tumor burden is too
great for the animal. Tumor volume would be followed throughout the duration of the
experiment, from first treatment until sacrifice. The tumor volume growth curves would
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then be analyzed to determine whether the tumor growth rate decreased, stayed the same,
or increased after cessation of YW152F treatment.
In addition to the possibility of immediate tumor rebound, the possibility of long
term toxic effects of YW152F therapy must also be considered. Initially, DLL4 was
believed to be expressed only by endothelial tip cells in actively sprouting vessels of
growing tissues or tumors, and was therefore expected to be a relatively tumor specific
target. However, DLL4 is now known to be expressed in the thymus and important for T
cell maturation. This indicates a potential risk for a severely compromised immune
system when DLL4 is systemically inhibited in patients. Further, Yan et al recently
demonstrated pathologic changes in the livers of mice, rats, and monkeys after 8 or 12
weeks of YW152F therapy. Long term YW152F treatment caused dilation of
centrilobular hepatic sinusoids, bile ductular proliferation, and atrophy of centrilobular
hepatic cords. No lethality occurred due to these changes; the animals were sacrificed
after 12 weeks in the experimental design85. Whether the observed liver toxicity is
permanent or reversible after cessation of therapy remains to be determined.
The observed liver pathology serves as a warning of possible unforeseen toxicity
using anti-DLL4 therapy. However, the method of inhibiting DLL4 may affect the
toxicity caused; inhibition of DLL4 with YW152F may have greater toxicity, for
example, than DLL4 inhibition by REGN421, the DLL4 targeting antibody currently in
Phase I trials. One purpose of a Phase I trial is to determine toxicity of the therapy.
Careful attention should be given to any reports of adverse side effects generated by use
of REGN421 in the adult population before anti-DLL4 therapy is tested in pediatric
patients.
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Targeting VEGF and DLL4 in Combination Studies
VEGF and DLL4 are key regulators of vessel development during both
physiologic and pathologic conditions. The essential role of both molecules is
demonstrated by the fact that VEGF and DLL4 are the only two known proteins involved
in vascular development for which haploinsufficiency is embryonically lethal 61. VEGF
stimulates endothelial cell proliferation and sprouting; DLL4 inhibits these processes.
VEGF can be imagined as the gas that increases vascular growth while DLL4 is the brake
that stops vessel branching and growth. A precise balance between VEGF and DLL4 is
needed for the development of a properly organized, mature vasculature. It makes sense,
then, that the two to regulate each other in a feedback loop. VEGF-A induces DLL4
expression in cultured human endothelial cells 53,56,86. DLL4 then activates Notch, and
Notch signaling inhibits VEGFR2 expression, effectively removing the receptor target of
VEGF on endothelial cells, and preventing further sprouting 53.
The relationship between VEGF and DLL4 has also been demonstrated in vivo, in
both developing mouse retinas and tumor models. Intravitreal injection of VEGF165 led
to increased DLL4 expression in mouse retinal vasculature within 24 hours of treatment
73

. Conversely, inhibition of VEGF using VEGF Trap led to a nearly 80% reduction in

DLL4 mRNA expression in rat C6 gliomas, as assessed by microarray analysis 58.
The essential roles of both DLL4 and VEGF in tumor vascular development
imply that DLL4 may be an alternative therapeutic target for vascular inhibition in
tumors that are resistant to anti-VEGF therapy. This is supported by data from several
tumor models that are resistant to VEGF inhibition, including HT1080-RM (the resistant
subline of HT1080 fibrosarcoma cells), mouse mammary tumors, and PC3 tumors.
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Growth of each of these tumor models continues during anti-VEGF therapy but is
significantly inhibited by systemic delivery of soluble DLL4

58,87

. Additionally, mouse

WEHI3 tumors, which are resistant to treatment with a monoclonal antibody against
VEGF, were susceptible to growth inhibition by treatment with YW152F, the same DLL4
neutralizing antibody used in our studies56. This suggests that inhibition of DLL4 may be
an effective therapy even in tumors that are not sensitive to VEGF inhibition, or in
tumors that progress after an initial period of sensitivity to anti-VEGF therapy.
In addition to use as a single agent, anti-DLL4 therapy may be most effective in
combination with anti-VEGF therapy. The synergistic effect of anti-VEGF (avastin) and
anti-DLL4 (YW152F) therapies has already been demonstrated in MV522 lung
carcinoma xenografts, which are only moderately sensitive to either alone. The
combination of both VEGF and DLL4 neutralizing antibodies together yielded
significantly more growth inhibition than either single agent56.
Currently, the sensitivity of Ewing’s sarcoma to anti-VEGF therapy
(bevacizumab) in combination with chemotherapy is being evaluated in a phase 2 trial by
the Children’s Oncology Group (COG). We have previously demonstrated that DC101, a
VEGF receptor 2 inhibiting antibody, significantly inhibits the growth of Ewing’s
sarcoma in mice, indicating that a positive outcome of the COG trial is likely 88. Our
previous demonstration of Ewing’s sarcoma growth inhibition by DC101 combined with
the synergistic effects of YW152F and avastin in the treatment of lung carcinoma in mice
indicates that targeting DLL4 and VEGF together may be an effective therapy for the
treatment of Ewing’s sarcoma. Studies combining inhibitors of DLL4 and VEGF to treat
Ewing’s sarcoma tumor bearing mice are merited.
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DLL4 as a therapeutic target for metastatic disease
While the five year survival rate for patients with non-metastatic Ewing’s
sarcoma is nearly 70%, it remains at less than 25% for the majority of patients, those with
meatastatic disease 1. Thus, there is a need for identifying therapeutic targets that may be
important for the growth of metastatic lesions. DLL4 may be involved in vasculogenesis
in metastatic lesions as well as primary tumors. We evaluated 14 patient samples for
DLL4 expression. Of these, 6 were metastatic lesions. DLL4 was expressed in a
perivascular pattern in metastatic tumors similar to the pattern observed in primary
tumors and xenograft models. Additionally, BM-derived cells participate in
vasculogenesis in TC71 cell lung metastases in mice (unpublished data, Zichao Zhou).
We have therefore confirmed that DLL4 is present around blood vessels in metastases
and that BM-derived cells are also present. Further studies are needed to determine
whether DLL4 inhibition would significantly impact vasculogenesis in metastases and
metastatic growth.
Recently, Wang et al reported the development of an orthotopic xenograft model
of Ewing’s sarcoma, TC-W, in which 54% of mice developed pulmonary metastases 89.
This model could be utilized to study the potential effects of inhibiting DLL4 on
metastatic development. Two interesting questions that should be addressed are: 1. Can
DLL4 inhibition be used before the appearance of detectable metastatic disease to prevent
formation of macrometastases? 2. Is DLL4 inhibition therapy effective against substantial
metastatic disease?
To determine whether anti-DLL4 therapy such as YW152F can prevent formation
of metastatic lesions, TC-W cells could be labeled with luciferase, injected into the rib
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bone and allowed to form tumors. Lungs can then be monitored for tumor cells using
bioluminescence imaging. Prior to the formation of detectable metastases, bi-weekly
treatment with YW152F or IgG control would be administered. The experiment would be
allowed to continue until mice must be sacrificed due to metastatic tumor burden, at
which time the number and size of metastatic lesions between treatment and control
groups would be compared.
To determine whether anti-DLL4 therapy would be effective against substantial
metastatic disease, TC-W cells could again be labeled with luciferase and injected into
mice rib bones. Again, the lungs would be monitored using bioluminescent imaging. In
this experimental schema, treatment with YW152F or IgG would not be started until after
significant detectable disease is present in the lungs. Treatment with YW152F or IgG
would then be begun to determine whether the growth rate of the metastatic lesions is
affected by DLL4 inhibition.
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Chapter 8
Materials and Methods
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A4573 and TC71 Ewing’s Sarcoma cell culture and mouse models
A4573 and TC71 cells were grown in Dulbecco’s Modified Eagle Medium
(company) supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 1
mmol/L nonessential amino acids, 1 mmol/L penicillin-streptomycin, and a two-fold
vitamin solution (Life Technologies, Inc., Grand Island, NY). Cells were used between
passage 3 and 7.
All animal experiments were approved by the Institutional Animal Care and Use
Committee at The University of Texas M.D. Anderson Cancer Center. For GFP BM
transplant experiments, donor mice were purchased from the M.D. Anderson Cancer
Center Genetic Mouse Engineering Facility (Jackson Laboratory Strain 003115). The
mice express enhanced GFP under control of the CMV-enhanced chicken β-actin
promoter. This strain of mice was used for all experiments where mice were treated with
shRNA. When these GFP mice were no longer available for purchase, GFP transgenic
mice were purchased from Jackson laboratories (Strain C57BL/6-Tg(UBCGFP)30Scha/J). These mice express enhanced GFP under control of the human ubiquitin
C promoter. This strain of GFP mice was used for all experiments where mice were
treated with YW152F. Recipient mice were athymic nu/nu nude mice. Nude mice were
purchased at six weeks old from either the National Cancer Institute (strain 01B70) or
Charles River (strain nu/nu 088).
GFP BM Transplant
For all experiments where mice received bone marrow transplants, the following
standard procedure was followed. BM was collected from GFP transgenic mice. Femurs
were collected, bone ends were clipped with scissors, and flushed with PBS using a
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sterile syringe and 30 gauge needle. Cells collected by flushing were pelleted and then
resuspended in PBS. Nude mice were given 900 rads whole body irradiation using a
Cesium irradiator (137Cs Mark 1 Irradiator; J. L. Shepherd & Associates, Glendale, CA).
This dose is sufficient to eradicate endogenous BM. Irradiated mice were then rescued by
i.v. injection of previously collected GFP+ BM cells. Each mouse received 1 x 106 GFP+
BM cells in 100 ul PBS. After transplant, four to six weeks was allowed for BM cell
engraftment before injection of tumor cells. At the end of each experiment, bone marrow
was collected from at least three representative mice to confirm GFP expression. Greater
than 90% of BM cells were GFP+ by flow cytometry (BD FACSAria, BD Biosciences).
shRNA vector and polyethylenimine (PEI). shRNA targeting mouse DLL4 (shDLL4)
was made by annealing the DNA oligomer 5’GATCCAGTCACTTGGGTGCAGTGTTTCAAGAGAACACTGCACCCAAGTGACT
TTTTTTGGAAA-3’ to its complimentary sequence. This double stranded oligomer was
then annealed into pSilencer 2.1-U6 hygro (Ambion, Austin, TX) shRNA vector between
the BamHI and HindIII sites. pSilencer 2.1-U6 hygro containing a sequence with minimal
homology to the mouse genome was used for the sh- control.
shRNA was delivered to tumors in PEI (Mr 25,000, branched form; Aldrich Chemical,
Milwaukee, WI). A stock solution of PEI (pH 7.0 – 7.5) was prepared at a concentration
of 4.3 mg/ml (0.1 M nitrogen) in PBS. PEI:shRNA complexes were prepared at a PEI
nitrogen:DNA phosphate ratio of 10:1 and a PEI:DNA ratio of 1.29:1 (w/w). DNA and
PEI were diluted in H2O so that the final volumes were the same for each solution. DNA
was then added dropwise to PEI while vortexing, for a final concentration of 0.4 μg DNA
per 1 μl PEI/DNA mixture.
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shRNA treatment in vivo
Nude mice that had previously received a GFP BM transplant (described above)
were injected subcutaneously with 2 x 106 TC71 cells on both right and left flanks. Five
days later, tumors were palpable and intratumor injections were begun. Left side tumors
were injected with PEI/sh- control while right side tumors were injected with
PEI/shDLL4. Each tumor received a total of 50 μl PEI/DNA mixture (20 μg DNA) per
treatment. Twenty-four days later (12 total treatments), final tumor volumes were
recorded, mice were sacrificed and tumors were harvested for examination by
immunohistochemistry. This experiment was repeated three times (n = 6, n = 8, and n
=13). In the third experiment, mice were injected with hypoxyprobe 2.5 hours prior to
sacrifice and Hoescht 33342 one minute prior to sacrifice, as described below.
Hoescht 33342 in vivo
For experiments where Hoescht 33342 was used to label functional vessels prior
to sacrifice, Hoescht 33342 was resuspended in sterile H2O at a concentration of
12mg/mL. Mice received i.v. injection of 100μl (1.2mg) of Hoescht33342 solution at
varying time points (1-5 minutes) prior to sacrifice. Mice were sacrificed by cervical
dislocation and tumors were harvested immediately after sacrifice.
Hypoxyprobe (pimonidazole HCl)
Hypoxyprobe-1 (HPI, inc, Burlington, MA) was reconstituted in PBS at a final
concentration of 7mg/mL. Two hours and thirty minutes prior to sacrifice, mice received
i.v. injections of 200 μl of hypoxyprobe/PBS solution (total 1.4mg hypoxyprobe).
Pimonidazole adducts (hypoxic cells) were detected by immunohistochemistry. Slides
were first incubated with mouse Fab fragment (Jackson Immunoresearch) diluted 1:10 in
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4% fish gel blocking solution overnight. Slides were then washed with PBS and
incubated with mouse anti-mouse monoclonal anti-hypoxyprobe antibody, diluted 1:800
in 4% fish gel for 3 hours. Slides were again washed with PBS, then incubated with antimouse Cy5, diluted 1:1000 in 4% fish gel for 1 hour. Images were captured by confocal
microscopy as described in the microscopy section of materials and methods.
YW152F in vivo experiments
Experiments using YW152F DLL4-neutralizing antibody were performed with
either TC71 or A4573 xenograft models. For all experiments, a GFP BM transplant was
performed and at least four weeks were allowed for BM cell engraftment before tumor
inoculation. After this period, mice were injected subcutaneously with either 2 x 106
TC71 or 6 x 106 A4573 cells. Five days later, mice were randomly divided into either
treatment or control groups. Mice were treated twice weekly by i.v. injection of either
YW152F (1.3mg YW152F in 100μl PBS), IgG (1 mg human IgG in PBS, Southern
Biotech, Birmingham, AL), or 100 μl PBS. TC71 cells were allowed to grow for a total
of 21 days (5 treatments), and A4573 for 24 days (6 treatments). Tumor volumes were
measured using calipers twice weekly and on the day of sacrifice. Mice were sacrificed
by euthanasia or cervical dislocation and tumors were harvested and frozen for
immunohistochemistry.
Experiments treating mice with TC71 tumors were done three times. In the first
experiment, n = 9 for YW152F and n= 8 for PBS. In the second, n = 9 for YW152F, n =
9 for IgG, and n = 7 for PBS. In the third, n = 6 for YW152F and n = 7 for IgG. In the
third experiment, mice were injected with hypoxyprobe 2.5 hours prior to sacrifice and
biotin was delivered by cardiac perfusion immediately following sacrifice.
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Experiments treating mice with A4573 tumors were performed twice. Both times,
n = 9 for YW152F and n =8 for IgG treated groups.
Biotin perfusion
For vessel perfusion studies using biotin, mice were sacrificed by cervical
dislocation and a 23 gauge needle was inserted into the left ventricle of the heart. 10 mL
of PBS was perfused through each animal to flush the circulation, followed by perfusion
with 8 mL of EZ Link Sulfo-NHS-Biotin in PBS (0.5mg/ml, Pierce Chemicals,
Rockford, IL). Immediately following perfusion, tumors were harvested and frozen for
immunohistochemistry.
YW152F in vitro
1.33 x 105 TC71 or A4573 cells per well were plated in 6 well dishes in complete
DMEM growth media. One day after seeding, YW152F or IgG was added to the media.
Two doses, 2.8μg/ml and 5μg/ml, were tested. Media was changed and fresh YW152F or
IgG was added daily. Total cell number and viability were counted at 48 and 72 hours by
automated trypan blue assay and ViCell (Beckman Coulter, Brea,CA). Experiments were
done two times in triplicate each time.
MigR1/mDLL4 plasmid
The retroviral MigR1 plasmid containing mouse DLL4 was constructed by
excising the full length mouse DLL4 gene out of pCR2.1/mDLL4 vector kindly provided
by Amgen (Thousand Oaks, CA) using EcoR1 restriction enzyme, and isolating the
DLL4 portion using agarose gel purification. MigR1 was then cut using EcoR1 restriction
enzyme in the presence of alkaline phosphatase per manufacturers instructions (New
England Biosciences, Ipwich, MA). The mouse DLL4 DNA was then ligated into the
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EcoR1 restriction enzyme site of cut MigR1 using T4 DNA ligase (New England
Bioscienes).
MigR1 control, MigR1/DNMAM, MigR1/NICD1, MigR1/NICD2, MigR1/NICD3,
MigR1/NICD4 plasmids
All MigR1 plasmids except those containing human or mouse DLL4 were the
kind gift of Dr. Patrick Zweidler-McKay (The University of Texas M.D. Anderson
Cancer Center, Houston,TX). The intracellular domains of each of the Notch receptors
were cloned between the EcoRI and BglI cloning sites under control of the MSCV LTR
retroviral promoter. There is an internal ribosome entry site (IRES) between the Notch
intracellular domain and enhanced GFP, so that the two are not expressed as a fusion
protein. For MigR1/DNMAM, a 61 amino acid portion of mastermind like 1 is directly
fused to enhanced GFP.
10T1/2 transfected with MigR1/ NICD1, MigR1/ NICD2, MigR1/ NICD3, MigR1/
NICD4, MigR1/DLL4
10T1/2 cells were purchased from ATCC (cell line C3H/10T1/2, Clone 8) and
were cultured in complete DMEM media as described above for TC71 and A4573 cells.
Transfection of 10T1/2 cells with MigR1 plasmids was done using Fugene 6 transfection
reagent (Roche, San Fransisco, CA) per manufacturer’s instructions. 2 μg of DNA was
used for each transfection in a six well dish. 48 hours after transfection, efficiency was
checked visually by looking for GFP expression. RNA was then collected using trizol
(Invitrogen, Carlsbad, CA) per manufacturer’s instructions.
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Immunohistochemistry
Xenograft Models Frozen slides were permeabalized by submersion in acetone for 10
minutes followed by incubation in PBS. Slides were then blocked in 4% fish gelatin for
20 minutes. For mouse anti-mouse primary antibodies, slides were then incubated
overnight in mouse Fab fragment blocking solution (mouse Fab diluted 1:10 in 4% fish
gel). Primary antibodies were diluted as indicated in 4% fish gel (table 1). Tissues were
incubated with primary antibodies for 3 hours or overnight. Slides were then washed in
PBS and incubated with 4% fish gel for ten minutes before addition of secondary
fluorescent antibodies. All secondary antibodies were diluted 1:1000 in 4% fish gel and
left on the tissue sections for one hour before slides were again washed with PBS. Nuclei
were stained with either Hoescht 33342 for 3 minutes or Sytox Green for 10 minutes.
Patient Samples Fourteen paraffin embedded Ewing’s sarcoma patient samples were
obtained from the tumor bank at M.D. Anderson Cancer Center. These samples represent
both primary and metastatic lesions from a total of ten different patients. The Institutional
Review Board at M.D. Anderson approved the use of human specimens for this study.
Deparaffinization and rehydration was performed by sequential submersion in xylene for
4 minutes, fresh xylem for 3 minutes, absolute ethanol for 2 minutes, fresh absolute
ethanol for 2 minutes, 95% ethanol for 1 minute, fresh 95% ethanol for 1 minute, 80%
ethanol for 1 minute, and PBS for 3 minutes. Antigen retrieval was performed by
incubation with pepsin at 37°C for thirty minutes, and endogenous peroxidase was
blocked with 3% H2O2. To detect DLL4, slides were then blocked with normal horse
serum and normal goat serum for ten minutes followed by incubation with rabbit antiDLL4 (Abcam) diluted 1:750 in normal horse serum and normal goat serum for three
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hours. Slides were then washed with PBS, and incubated with peroxidase labeled
biotinylated goat anti-rabbit secondary antibody (Jackson Immunoresearch). DLL4+ cells
were detected with 3,3’-diaminobenzidine (DAB; Open Biosystems, Huntsville, AL)
which turns brown on positive cells, and counterstained with Gill’s hematoxylin (SigmaAldrich). Tumors were scored in a qualitative manner as either DLL4 positive or DLL4
negative.
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Dilution Factor

company

rabbit anti-mouse/human DLL4

1000

Abcam, Cambridge, MA

rabbit anti-human DLL4

1000

Cell Signaling Technology, Danvers, MA

anti-mouse-a-SMA-Cy3

200

Sigma-Aldrich, St. Louis, MO

mouse anti-mouse a-SMA

100

Abcam, Cambridge, MA

rabbit anti-mouse desmin

400

Abcam, Cambridge, MA

rabbit anti-GFP

1000

Santa Cruz Biotechnology, Santa Cruz, CA

chicken anti-GFP

400

Abcam, Cambridge, MA

rabbit anti-mouse NG2

500

Millipore, Billerica, MA

rabbit anti-mouse S100A4

1000

Abcam, Cambridge, MA

rat anti-mouse CD31

1000

BD Biosciences, Franklin Lakes, NJ

rabbit anti-human/mouse NICD1

1000

Cell Signaling Technology, Danvers, MA

rabbit anti-human Notch1

1000

Abcam, Cambridge, MA

mouse anti-mouse hypoxyprobe-1

800

HPI, inc., Burlington, MA

Alexa Flour 488 (anti-rat, anti- rabbit)

1000

Molecular Probes, Eugene, OR

Alexa Flour 594 (anti-rabbit)

1000

Molecular Probes, Eugene, OR

Cy3 (anti-rat, anti-rabbit, anti-mouse)

1000

Jackson Immunoresearch, West Grove, PA

Cy5 (anti-rat, anti-mouse, anti-rabbit)

1000

Jackson Immunoresearch, West Grove, PA

Primary Antibodies

Secondary Antibodies

Table 2. Immunohistochemistry antibodies used on frozen sections. Antibodies used
for immunohistochemistry are listed. Antibodies were diluted in 4% fish gelatin in PBS
by the dilution factor listed.
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Microscopy
For non-confocal fluorescent microscopy, Images were captured using using a
Zeiss Axioplan fluorescence microscope (Carl Zeiss, Inc., Thornwood, NY) equipped
with a 100-W Hg lamp and narrow bandpass excitation filters. Representative images
were obtained using a cooled charge-coupled device Hamamatsu C5810 camera
(Hamamatsu Photonics, Bridgewater, NJ) and Optimas imaging software (Media
Cybernetics, Bethesda, MD). For confocal microscopy, images were collected using a
Zeiss Laser Confocal Microscope, and LSM software (Carl Zeiss MicroImaging, Inc.,
Thornwood, NY).
Immunohistochemistry Quantification
Five random 10x-magnification fields were captured on each slide. A minimum
and maximum fluorescent intensity was set for positive staining for each antibody.
Positive areas for each marker were measured using Simple PCI software (Hamamatsu,
Sewickley, PA). For each of the five fields per slide, we measured the mean pixel area of
positive fluorescence for the protein of interest as well as the mean pixel area for nuclei
and a mean positive pixel:nuclei ratio was calculated.
Tumor homogenization and collection of GFP+ BM-derived cells
GFP BM transplants were performed on nude mice. One month later, 2 x 106
TC71 cells were implanted subcutaneously. Tumors were allowed to grow until they
reached 2cm3. Mice were then sacrificed, tumors were harvested, and minced using a
razor blade. Tumor pieces were then passaged through progressively smaller needles and
incubated with collagenasese 1 (2mg/mL) in DMEM at 37 degrees Celsius while rotating
for 45 minutes. Tumor homogenate was then passaged through a filter with 100μm pores,
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until a single cell suspension was achieved. GFP+ (BM-derived) cells were then collected
from the cell suspension using FACS, and RNA was collected from these GFP+ cells.
PCR primers
DLL4 Forward: 5’actcaccactctccgtgcaagaat Reverse: 5’tgtgtaacagccggttcactcctt
Hes1 Forward: 5’caacacgacaccggacaaaccaaa Reverse: 5’ ttccggaggtgcttcacagtcatt
Hey1 Forward: 5’ tcagatgcgcagctttactggaga Reverse: 5’ tttcagactccgatcgtctacgca
Hey2 Forward: 5’ acttgaaagcagcacaccaacgtc Reverse: 5’ tggaggcttcggtggaattgctta
RGS5 Forward: 5’ tcaagttgaggatctaagccgcca Reverse:5’ ttctcacaggcaacccagaactca
Desmin Forward: 5’ tcgtattgacctggagcgcagaat Reverse:5’ atgttcttagccgcgatggtctca
PDGFR-β Forward: 5’aaacacaccttcttgcagcgacac Reverse: 5’attaaggtggcgcgataggtcctt
Real-time Hes1 Forward: 5’ gctgctaccccagccagtgt Reverse: 5’ gcccttcgcctcttctccat
Real-time Hey1 Forward: 5’ tggcctgcttggcttttctc Reverse: 5’ gccaagtgcaggcaaggtct
Real-time Hey2 Forward: 5’ accactgggcagctgctttc Reverse: 5’ atgggcaaacgttgctgtga
Real-time RGS5 Forward: 5’ taagccgccagccaaaatgt Reverse: 5’ gtgtgccttggcaggcttct
Real-time desmin Forward: 5’ gagccaggcctactcgtcca Reverse: 5’ tgaactcgaggagcccttgg
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Greater than 90% of BM cells are GFP+ after GFP BM transplant in nude mice
At the end of all in vivo experiments, bone marrow is collected from three random
representative mice and is examined by flow cytometry for the presence of GFP+ cells.
GFP+ cells consistently made up greater than 90% of the BM in transplanted mice. In a
representative experiment, 94.5% of BM cells collected from a nude mouse 51 days after
GFP transplant were GFP+ compared to 0.19% in a non-transplanted nude mouse control
(Figure A1).

Nude mouse control

51 days post-transplant

Data.001

Data.006

0.19

100

101

102
FL1-H

GFP

103

94.5

104

100

101

102
FL1-H

103

104

GFP

Figure A1. After GFP BM transplant, greater than 90% of BM cells are GFP+.
Whole BM was collected from the femurs of nude mice that had not received any bone
marrow transplant, or from nude mice 51 days after GFP BM transplant. Flow cytometry
was performed to measure the percent of cells that are GFP+. Representative data from
one mouse in each group is presented. 0.19% of BM cells from the nude mouse control
were GFP compared to 94.5% of BM cells from the mouse that had received a GFP BM
transplant.
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Hoescht 33342 in vivo perfusion studies were inconclusive
As explained in Chapter 4, we attempted to measure blood vessel perfusion in
tumors using tail vein injections of Hoescht33342 sixty seconds prior to sacrifice. Due to
the excessive labeling of nuclei throughout the tumor, it was difficult to determine which
vessels had blood flow and which did not. Representative images of tumors after
Hoescht33342 perfusion are shown in figure A2.

Figure A2. Hoescht33342 perfusion studies were inconclusive. Mice bearing bilateral
tumors received tail vein injections of Hoescht33342 in H2O sixty seconds prior to
sacrifice. After sacrifice, tumors were harvested and immunohistochemistry was
performed for CD31 (green, to identify endothelial cells). Nuclei labeled by the leaking
of Hoescht33342 out of functional vasculature are blue.

MigR1/DLL4 increases mouse DLL4 expression and shDLL4 inhibits mouse DLL4
expression in vitro
I constructed the retroviral MigR1/DLL4 plasmid by PCR amplification of the
mouse DLL4 gene and insertion of this gene into the multiple cloning site of the MigR1
retroviral vector (see materials and methods). Therefore, prior to using this plasmid as a
tool in my research, it was important to demonstrate that DLL4 was, in fact,
overexpressed in cells transfected with MigR1/DLL4. Human 293T cells were
transfected with MigR1/DLL4. Forty eight hours later, protein lysates were made and a
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western blot was run to probe for DLL4. DLL4 expression was increased in cells

MigR1/mDLL4 c

MigR1/mDLL4 b

MigR1/mDLL4 a

MigR1

no transfection

transfected with MigR1/DLL4 but not with MigR1 control (Figure A3).

DLL4
β-actin

Figure A3. MigR1/DLL4 increases
expression of mouse DLL4 in 293T
cells. Human 293T cells were
transfected with MigR1 or
MigR1/DLL4 plasmid isolated from
three different bacterial clones (a,b,c).
Forty eight hours later, western blot
was performed to probe for DLL4.
Clone A was used in all experiments
hereafter.

In addition to MigR1/DLL4, I constructed shDLL4 to inhibit mouse DLL4
expression by ligating two different sequences targeting DLL4 into a pSilencer2.0 hygro
plasmid (shDLL4-a and shDLL4-b). Prior to use in experiments, the efficacy of each
shDLL4 plasmid was demonstrated by transfecting SC9-19 mouse stromal cells, which
express DLL4, with shDLL4-a or shDLL4-b. Twenty-four hours later, RNA was
collected and RT-PCR for DLL4 was performed. Both shDLL4 plasmids inhibited DLL4
expression (Figure A4). Inhibition of DLL4 expression by shDLL4-a was most efficient,

shDLL4-b

shDLL4-a

No transfection

and this plasmid was used for all in vivo experiments described in this thesis.
Figure A4. shDLL4-a inhibits DLL4 mRNA
expression in mouse SC9-19 cells. SC9-19 cells
were transfected with shDLL4-a or shDLL4-b.
Twenty-four hours later, RNA was collected and
RT-PCR was performed to examine DLL4 RNA
levels.

DLL4
18s
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